metformin and Cancer of Pancreas
metformin has been researched along with Cancer of Pancreas in 182 studies
Metformin: A biguanide hypoglycemic agent used in the treatment of non-insulin-dependent diabetes mellitus not responding to dietary modification. Metformin improves glycemic control by improving insulin sensitivity and decreasing intestinal absorption of glucose. (From Martindale, The Extra Pharmacopoeia, 30th ed, p289)
metformin : A member of the class of guanidines that is biguanide the carrying two methyl substituents at position 1.
Research Excerpts
Excerpt | Relevance | Reference |
---|---|---|
"In people with metformin-treated diabetes, to evaluate the risk of acute pancreatitis, pancreatic cancer and other diseases of the pancreas post second-line anti-hyperglycaemic agent initiation." | 7.91 | Treatment with incretins does not increase the risk of pancreatic diseases compared to older anti-hyperglycaemic drugs, when added to metformin: real world evidence in people with Type 2 diabetes. ( Atherton, J; Green, JB; Montvida, O; Paul, SK, 2019) |
"Lymphoma and pancreatic cancer patients with type 2 diabetes were sorted into an experimental (metformin) group and a control (nonmetformin) group." | 7.91 | Metformin Associated With Increased Survival in Type 2 Diabetes Patients With Pancreatic Cancer and Lymphoma. ( Solomon, SS; Vacheron, A; Wynn, A; Zuber, J, 2019) |
"We evaluated the relationship between liraglutide and acute pancreatitis or pancreatic cancer in an ongoing post-marketing safety assessment programme." | 7.80 | A prospective, claims-based assessment of the risk of pancreatitis and pancreatic cancer with liraglutide compared to other antidiabetic drugs. ( Chan, KA; Funch, D; Gydesen, H; Major-Pedersen, A; Tornøe, K, 2014) |
" Since improvement of β-cell viability is a promising anti-diabetic strategy, the protective effect of metformin, a known insulin sensitizer was studied in rat insulinoma cells." | 7.80 | Metformin attenuates palmitate-induced endoplasmic reticulum stress, serine phosphorylation of IRS-1 and apoptosis in rat insulinoma cells. ( Csala, M; Kéri, G; Kokas, M; Mandl, J; Simon-Szabó, L, 2014) |
"Metformin and aspirin have been explored as two emerging cancer chemoprevention agents for different types of cancers, including pancreatic cancer." | 6.50 | Repurposing of metformin and aspirin by targeting AMPK-mTOR and inflammation for pancreatic cancer prevention and treatment. ( DiPaola, RS; Tan, XL; Yang, CS; Yue, W, 2014) |
"Obesity has been linked to a higher risk of pancreatic cancer." | 5.91 | Metformin inhibits neutrophil extracellular traps-promoted pancreatic carcinogenesis in obese mice. ( Dai, S; Gao, H; Gao, Y; Jiang, K; Li, M; Lu, Z; Miao, Y; Wang, G; Yin, L; Zhang, J; Zhang, K, 2023) |
"Metformin use was not associated with overall survival in the complete analyses (HR = 1." | 5.56 | Metformin Use and Pancreatic Cancer Survival among Non-Hispanic White and African American U.S. Veterans with Diabetes Mellitus. ( Carson, KR; Chang, SH; Drake, BF; Luo, S; Sanfilippo, KM; Thomas, TS; Toriola, AT, 2020) |
"Metformin was associated with increased PFS of patients receiving somatostatin analogues and in those receiving everolimus, with or without somatostatin analogues." | 5.48 | Metformin Use Is Associated With Longer Progression-Free Survival of Patients With Diabetes and Pancreatic Neuroendocrine Tumors Receiving Everolimus and/or Somatostatin Analogues. ( Antonuzzo, L; Aroldi, F; Bajetta, E; Berardi, R; Bongiovanni, A; Brighi, N; Brizzi, MP; Buzzoni, R; Campana, D; Carnaghi, C; Catena, L; Cauchi, C; Cavalcoli, F; Cingarlini, S; Colao, A; Concas, L; Davì, MV; de Braud, F; De Divitiis, C; Delle Fave, G; Di Costanzo, F; Di Maio, M; Duro, M; Ermacora, P; Faggiano, A; Fazio, N; Femia, D; Fontana, A; Garattini, SK; Giacomelli, L; Giuffrida, D; Ibrahim, T; La Salvia, A; Lo Russo, G; Marconcini, R; Massironi, S; Mazzaferro, V; Milione, M; Ortolani, S; Panzuto, F; Perfetti, V; Prinzi, N; Puliafito, I; Pusceddu, S; Razzore, P; Ricci, S; Rinzivillo, M; Spada, F; Tafuto, S; Torniai, M; Vernieri, C; Zaniboni, A, 2018) |
"Metformin treatment itself conferred better OS in comparison within DM patients (HR 0." | 5.43 | The Impact of Diabetes Mellitus and Metformin Treatment on Survival of Patients with Advanced Pancreatic Cancer Undergoing Chemotherapy. ( Bang, YJ; Choi, Y; Han, SW; Im, SA; Kim, TY; Lee, KH; Oh, DY, 2016) |
" In this article, we discuss the potential correlation between glycemic status, administration of antiglycemic treatments, such as metformin or insulin, and prognosis of pancreatic neuroendocrine tumors patients treated with everolimus and octreotide, on the basis of existing evidence and our experience." | 4.93 | Metformin with everolimus and octreotide in pancreatic neuroendocrine tumor patients with diabetes. ( Buzzoni, R; Concas, L; de Braud, F; Femia, D; Formisano, B; Giacomelli, L; Leuzzi, L; Marceglia, S; Mazzaferro, V; Milione, M; Pusceddu, S; Vernieri, C, 2016) |
" We performed a systematic review and meta-analysis evaluating the effect of metformin, sulfonylureas (SUs), thiazolidinediones (TZDs), and insulin on the risk of PaC in patients with diabetes mellitus (DM)." | 4.89 | Anti-diabetic medications and risk of pancreatic cancer in patients with diabetes mellitus: a systematic review and meta-analysis. ( Chari, ST; McWilliams, RR; Murad, MH; Singh, AG; Singh, PP; Singh, S, 2013) |
"In people with metformin-treated diabetes, to evaluate the risk of acute pancreatitis, pancreatic cancer and other diseases of the pancreas post second-line anti-hyperglycaemic agent initiation." | 3.91 | Treatment with incretins does not increase the risk of pancreatic diseases compared to older anti-hyperglycaemic drugs, when added to metformin: real world evidence in people with Type 2 diabetes. ( Atherton, J; Green, JB; Montvida, O; Paul, SK, 2019) |
"Lymphoma and pancreatic cancer patients with type 2 diabetes were sorted into an experimental (metformin) group and a control (nonmetformin) group." | 3.91 | Metformin Associated With Increased Survival in Type 2 Diabetes Patients With Pancreatic Cancer and Lymphoma. ( Solomon, SS; Vacheron, A; Wynn, A; Zuber, J, 2019) |
"Metformin inhibited pancreatic cancer initiation, suppressed chronic pancreatitis-induced tumorigenesis, and showed promising therapeutic effect in PDAC." | 3.85 | Metformin suppresses cancer initiation and progression in genetic mouse models of pancreatic cancer. ( Cao, J; Chen, K; Cheng, L; Duan, W; Gao, L; Jiang, Z; Lei, M; Li, J; Ma, Q; Qian, W; Sun, L; Yan, B; Zhou, C, 2017) |
"Metformin treatment is associated with a decreased risk and better prognosis of pancreatic cancer (PC) in patients with type 2 diabetes, but the mechanism of metformin's PC growth inhibition in the context of a prediabetic state is unknown." | 3.81 | Metformin and Rapamycin Reduce Pancreatic Cancer Growth in Obese Prediabetic Mice by Distinct MicroRNA-Regulated Mechanisms. ( Cifarelli, V; Devlin, KL; Dunlap, SM; Huang, J; Hursting, SD; Kaaks, R; Lashinger, LM; Pollak, MN, 2015) |
"We explored if known risk factors for pancreatic cancer such as type II diabetes and chronic inflammation, influence the pathophysiology of an established primary tumor in the pancreas and if administration of metformin has an impact on tumor growth." | 3.81 | Impact of diabetes type II and chronic inflammation on pancreatic cancer. ( Albert, AC; Amme, J; Bürtin, F; Partecke, LI; Radecke, T; Vollmar, B; Zechner, D, 2015) |
"We evaluated the relationship between liraglutide and acute pancreatitis or pancreatic cancer in an ongoing post-marketing safety assessment programme." | 3.80 | A prospective, claims-based assessment of the risk of pancreatitis and pancreatic cancer with liraglutide compared to other antidiabetic drugs. ( Chan, KA; Funch, D; Gydesen, H; Major-Pedersen, A; Tornøe, K, 2014) |
" Since improvement of β-cell viability is a promising anti-diabetic strategy, the protective effect of metformin, a known insulin sensitizer was studied in rat insulinoma cells." | 3.80 | Metformin attenuates palmitate-induced endoplasmic reticulum stress, serine phosphorylation of IRS-1 and apoptosis in rat insulinoma cells. ( Csala, M; Kéri, G; Kokas, M; Mandl, J; Simon-Szabó, L, 2014) |
" Here, we show that treatment of pancreatic ductal adenocarcinoma (PDAC) cells (PANC-1, MiaPaCa-2) with the isoquinoline alkaloid berberine (0." | 3.80 | Dose-Dependent AMPK-Dependent and Independent Mechanisms of Berberine and Metformin Inhibition of mTORC1, ERK, DNA Synthesis and Proliferation in Pancreatic Cancer Cells. ( Eibl, G; Ming, M; Rozengurt, E; Sinnett-Smith, J; Soares, HP; Wang, J; Young, SH, 2014) |
"Metformin is a biguanide, widely used as a first‑line oral drug in treating type 2 diabetes." | 3.01 | Research progress on the therapeutic effect and mechanism of metformin for lung cancer (Review). ( Han, P; Liu, Q; Sun, K; Xiang, J; Zhou, J, 2023) |
" The recommended dose of metformin combined with nivolumab is determined in part 1." | 2.87 | Study Protocol: Phase-Ib Trial of Nivolumab Combined With Metformin for Refractory/Recurrent Solid Tumors. ( Fujiwara, T; Hotta, K; Kiura, K; Kozuki, T; Kubo, T; Ninomiya, T; Okada, H; Toyooka, S; Udono, H, 2018) |
"In 2020, GLOBOCAN reported that pancreatic cancer accounts for 4." | 2.82 | Pharmacological Modulation of Apoptosis and Autophagy in Pancreatic Cancer Treatment. ( Islam, MK; Lian, HK; Lim, JCW; Sagineedu, SR; Selvarajoo, N; Stanslas, J, 2022) |
"Metformin dose was escalated from 500 mg (in the first week) to 1000 mg twice daily in the second week." | 2.80 | Metformin in patients with advanced pancreatic cancer: a double-blind, randomised, placebo-controlled phase 2 trial. ( Beeker, A; Kordes, S; Mathôt, RA; Pollak, MN; Punt, CJ; Richel, DJ; Weterman, MJ; Wilmink, JW; Zwinderman, AH, 2015) |
"At the time of diagnosis, almost 80% of pancreatic cancer patients present with new-onset type 2 diabetes (T2D) or impaired glucose tolerance." | 2.79 | Tumour-educated macrophages display a mixed polarisation and enhance pancreatic cancer cell invasion. ( Andersson, R; Karnevi, E; Rosendahl, AH, 2014) |
"Metformin and BBR both activate AMP-activated protein kinase (AMPK) which is a key mediator of glucose metabolism." | 2.61 | Abilities of berberine and chemically modified berberines to interact with metformin and inhibit proliferation of pancreatic cancer cells. ( Abrams, SL; Akula, SM; Bueno-Silva, B; Candido, S; Cervello, M; Follo, MY; Gizak, A; Lertpiriyapong, K; Libra, M; Lin, HL; Lombardi, P; Mao, W; Martelli, AM; Matias de Alencar, S; McCubrey, JA; Montalto, G; Murata, RM; Rakus, D; Ramazzotti, G; Ratti, S; Rosalen, PL; Steelman, LS, 2019) |
"Metformin use was associated with better overall survival among pancreatic cancer patients (meta-HR = 0." | 2.58 | Effect of Metformin and Statin Use on Survival in Pancreatic Cancer Patients: a Systematic Literature Review and Meta-analysis. ( Graber, JM; Lin, Y; Lu, SE; Lu-Yao, G; Tan, XL, 2018) |
"Metformin is a widely used antidiabetic drug, and there is evidence among diabetic patients that metformin is a chemopreventive agent against multiple cancers." | 2.58 | Metformin-induced anticancer activities: recent insights. ( Karki, K; Nair, V; Safe, S, 2018) |
"Pancreatic cancer is a highly lethal disease with a poor prognosis while metformin has been associated with a decreased risk of pancreatic cancer." | 2.55 | Metformin is associated with survival benefit in pancreatic cancer patients with diabetes: a systematic review and meta-analysis. ( Li, B; Li, D; Li, YY; Liu, FR; Liu, YH; Wang, Q; Xu, C; Yao, Y; Zhang, MC; Zhou, PT, 2017) |
"Metformin is a cornerstone in the treatment of diabetes mellitus type 2." | 2.53 | Metformin and pancreatic cancer: Is there a role? ( De Souza, A; Khawaja, KI; Masud, F; Saif, MW, 2016) |
"Metformin use was associated with improved survival outcomes in patients with resected pancreatic cancer, but the difference was not statistically significant." | 2.53 | Effect of Metformin Use on Survival in Resectable Pancreatic Cancer: A Single-Institution Experience and Review of the Literature. ( Ambe, CM; Chen, L; Fulp, J; Mahipal, A; Malafa, MP, 2016) |
"We stress on the need for a better stratification of patients and a more rigorous planning of clinical trials not only focusing on classical parameters but also on potential predictive biomarkers (AMPK, mTOR, HIF-1α, IGF-1R) and metformin dosage for positive outcome." | 2.53 | Metformin in pancreatic cancer treatment: from clinical trials through basic research to biomarker quantification. ( Bhaw-Luximon, A; Jhurry, D, 2016) |
"Survival from pancreatic cancer remains poor." | 2.53 | The Role of Common Pharmaceutical Agents on the Prevention and Treatment of Pancreatic Cancer. ( Amin, S; Boffetta, P; Lucas, AL, 2016) |
"However, the function of aspirin use in pancreatic cancer largely remains unknown." | 2.53 | Aspirin in pancreatic cancer: chemopreventive effects and therapeutic potentials. ( Dai, JJ; Gu, DN; Huang, Q; Jiang, MJ; Tian, L, 2016) |
"Metformin and aspirin have been explored as two emerging cancer chemoprevention agents for different types of cancers, including pancreatic cancer." | 2.50 | Repurposing of metformin and aspirin by targeting AMPK-mTOR and inflammation for pancreatic cancer prevention and treatment. ( DiPaola, RS; Tan, XL; Yang, CS; Yue, W, 2014) |
"Clinicians and patients with type 2 diabetes enjoy an expanding list of medications to improve glycemic control." | 2.50 | Systematic reviews to ascertain the safety of diabetes medications. ( Brito, JP; Gionfriddo, MR; Leppin, AL; Montori, VM; Morey-Vargas, OL; Murad, MH, 2014) |
"However, its influence on pancreatic cancer was controversial." | 2.50 | Metformin is associated with reduced risk of pancreatic cancer in patients with type 2 diabetes mellitus: a systematic review and meta-analysis. ( Jiang, GL; Lai, ST; Ma, NY; Ren, ZG; Wang, Z; Xie, L; Zhao, JD; Zhu, J, 2014) |
"Although a correlation between pancreatic cancer and diabetes mellitus has long been suspected, the potential role diabetes mellitus plays in the pathogenicity of both hepatocellular carcinoma and colon cancer is becoming increasingly well defined." | 2.50 | Diabetes mellitus as a novel risk factor for gastrointestinal malignancies. ( Herrigel, DJ; Moss, RA, 2014) |
"Long-standing type 1 diabetes and type 2 diabetes increase the risk for this malignancy, but the cancer can also induce pancreatogenic, or type 3c, diabetes as well." | 2.49 | Diabetes and cancer: placing the association in perspective. ( Andersen, DK, 2013) |
"Diabetes or impaired glucose tolerance is present in more than 2/3rd of pancreatic cancer patients." | 2.48 | Diabetes and pancreatic cancer. ( Chari, ST; Muniraj, T, 2012) |
"Type 3 diabetes mellitus is an effect, and therefore a harbinger, of pancreatic cancer in at least 30% of patients." | 2.47 | Diabetes and pancreatic cancer: chicken or egg? ( Andersen, DK; Elahi, D; Magruder, JT, 2011) |
"Hepatic insulin resistance is characteristic of T3cDM and is caused by deficiencies of both insulin and pancreatic polypeptide." | 2.47 | Pancreatogenic diabetes: special considerations for management. ( Andersen, DK; Cui, Y, 2011) |
"Obesity has been linked to a higher risk of pancreatic cancer." | 1.91 | Metformin inhibits neutrophil extracellular traps-promoted pancreatic carcinogenesis in obese mice. ( Dai, S; Gao, H; Gao, Y; Jiang, K; Li, M; Lu, Z; Miao, Y; Wang, G; Yin, L; Zhang, J; Zhang, K, 2023) |
"The association between metformin and pancreatic cancer (PC) was explored using a WCE model within the framework of discrete-time Cox regression." | 1.91 | Reverse causation biases weighted cumulative exposure model estimates, but can be investigated in sensitivity analyses. ( Agay, N; Dankner, R; Freedman, LS; Murad, H; Olmer, L, 2023) |
"Inactivation of Numb promotes the pancreatic cancer radio-resistance through hyperglycemic memory and metformin could suppress the radio-resistance by activating Numb in vitro and in vivo." | 1.72 | Numb/Notch/PLK1 signaling pathway mediated hyperglycemic memory in pancreatic cancer cell radioresistance and the therapeutic effects of metformin. ( Fang, C; Liu, C; Xia, J; Zhu, D, 2022) |
"MM10 altered the OCR in prostate cancer cells." | 1.72 | EPR Investigations to Study the Impact of Mito-Metformin on the Mitochondrial Function of Prostate Cancer Cells. ( d'Hose, D; Gallez, B; Hardy, M; Jordan, BF; Mathieu, B; Mignion, L; Ouari, O; Sonveaux, P, 2022) |
"Metformin is a commonly prescribed antidiabetic drug that demonstrated a potent immune modulator effect and antitumor response." | 1.72 | Metformin enhances the antitumor activity of oncolytic herpes simplex virus HF10 (canerpaturev) in a pancreatic cell cancer subcutaneous model. ( Abdelmoneim, M; Aboalela, MA; Bustos-Villalobos, I; Eissa, IR; Kasuya, H; Kodera, Y; Matsumura, S; Naoe, Y; Sibal, PA; Tanaka, M, 2022) |
"KRas is frequently mutated in pancreatic cancers." | 1.62 | GSK-3β Can Regulate the Sensitivity of MIA-PaCa-2 Pancreatic and MCF-7 Breast Cancer Cells to Chemotherapeutic Drugs, Targeted Therapeutics and Nutraceuticals. ( Abrams, SL; Akula, SM; Candido, S; Cervello, M; Cocco, L; Duda, P; Falzone, L; Gizak, A; Libra, M; Martelli, AM; McCubrey, JA; Meher, AK; Montalto, G; Rakus, D; Ratti, S; Ruvolo, P; Steelman, LS, 2021) |
"The prognosis of pancreatic cancer is poor and new treatment strategies are urgently needed." | 1.62 | Use of non-cancer drugs and survival among patients with pancreatic adenocarcinoma: a nationwide registry-based study in Norway. ( Andreassen, BK; Botteri, E; Bouche, G; Pantziarka, P; Sloan, EK; Støer, NC, 2021) |
"Metformin use was not associated with overall survival in the complete analyses (HR = 1." | 1.56 | Metformin Use and Pancreatic Cancer Survival among Non-Hispanic White and African American U.S. Veterans with Diabetes Mellitus. ( Carson, KR; Chang, SH; Drake, BF; Luo, S; Sanfilippo, KM; Thomas, TS; Toriola, AT, 2020) |
"Metformin is an anti-hypoglycemic drug that appears to have anticancer effects." | 1.56 | Metformin Inhibits Proliferation and Tumor Growth of QGP-1 Pancreatic Neuroendocrine Tumor Cells by Inducing Cell Cycle Arrest and Apoptosis. ( Fujihara, S; Fujita, K; Fujita, N; Iwama, H; Kamada, H; Kato, K; Kobara, H; Kobayashi, K; Masaki, T; Morishita, A; Namima, D; Tsutsui, K; Yamana, H, 2020) |
"Metformin has plausible direct and indirect anti-cancer properties against pancreatic adenocarcinoma cells." | 1.56 | An observational study to justify and plan a future phase III randomized controlled trial of metformin in improving overall survival in patients with inoperable pancreatic cancer without liver metastases. ( Broadhurst, PJ; Hart, AR, 2020) |
"With human pancreatic cancer cell line PANC-1 as the study object, different concentrations of metformin were added for intervention." | 1.56 | Metformin reduces pancreatic cancer cell proliferation and increases apoptosis through MTOR signaling pathway and its dose-effect relationship. ( Jin, F; Wang, R; Zhao, HW; Zhao, JQ; Zhou, N, 2020) |
"Type 2 diabetes mellitus is associated with pNET metastasis and not an independent risk factor for poor prognosis in pNETs." | 1.56 | Diabetes Is Associated With the Metastasis of Pancreatic Neuroendocrine Tumors. ( Cheng, H; Fan, K; Fan, Z; Gong, Y; Huang, Q; Jin, K; Liu, C; Luo, G; Ni, Q; Yang, C; Yu, X, 2020) |
"Metformin is a drug used in the treatment of type 2 diabetes." | 1.56 | Metformin inhibits TGF‑β1‑induced epithelial‑mesenchymal transition and liver metastasis of pancreatic cancer cells. ( Endo, Y; Hirai, Y; Inoue, K; Ishikawa, T; Itoh, Y; Kamada, K; Matsumura, S; Mizushima, K; Naito, Y; Oka, K; Okayama, T; Ota, T; Sakamoto, N; Takagi, T; Uchiyama, K; Yoshida, J, 2020) |
"The GEM-resistant human pancreatic cancer PANC-1/GEM cell line was established, and the proliferation ability of PANC-1 and PANC-1/GEM cell lines was detected using the Cell Counting Kit-8 (CCK-8), which was then detected by flow cytometry after they were labeled by Ki67." | 1.51 | Mechanism of metformin enhancing the sensitivity of human pancreatic cancer cells to gem-citabine by regulating the PI3K/Akt/mTOR signaling pathway. ( Chen, XD; Qiao, ZG; Tang, JM; Wu, XY; Yao, XM; Zhou, HY, 2019) |
"Gemcitabine (GEM) has become the standard chemotherapy for PDAC; however, acquired resistance to GEM is a major challenge." | 1.51 | Mechanisms of metformin's anti‑tumor activity against gemcitabine‑resistant pancreatic adenocarcinoma. ( Kitagawa, Y; Suzuki, K; Suzuki, Y; Takeuchi, O, 2019) |
"Metformin promotes a survival benefit in individuals with PPDM but not PCRD." | 1.51 | Antidiabetic Medications and Mortality Risk in Individuals With Pancreatic Cancer-Related Diabetes and Postpancreatitis Diabetes: A Nationwide Cohort Study. ( Cho, J; Goodarzi, MO; Pandol, SJ; Petrov, MS; Scragg, R, 2019) |
"Metformin is a very frequently prescribed drug used to treat type II diabetes." | 1.48 | Metformin influences drug sensitivity in pancreatic cancer cells. ( Abrams, SL; Candido, S; Cervello, M; Cocco, L; Follo, MY; Gizak, A; Lertpiriyapong, K; Libra, M; Lombardi, P; Martelli, AM; McCubrey, JA; Montalto, G; Murata, RM; Rakus, D; Ratti, S; Rosalen, PL; Steelman, L; Suh, PG, 2018) |
"In this study, we evaluated in pancreatic cancer cells metformin, which blocks oxidative phosphorylation, in combination with α-cyano-4-hydroxycinnamate, which has been reported to inhibit the export of lactate from the cytosol." | 1.48 | α-cyano-4-hydroxycinnamate impairs pancreatic cancer cells by stimulating the p38 signaling pathway. ( Kerndl, H; Kumstel, S; Schönrogge, M; Vollmar, B; Zechner, D; Zhang, X, 2018) |
"Metformin was associated with increased PFS of patients receiving somatostatin analogues and in those receiving everolimus, with or without somatostatin analogues." | 1.48 | Metformin Use Is Associated With Longer Progression-Free Survival of Patients With Diabetes and Pancreatic Neuroendocrine Tumors Receiving Everolimus and/or Somatostatin Analogues. ( Antonuzzo, L; Aroldi, F; Bajetta, E; Berardi, R; Bongiovanni, A; Brighi, N; Brizzi, MP; Buzzoni, R; Campana, D; Carnaghi, C; Catena, L; Cauchi, C; Cavalcoli, F; Cingarlini, S; Colao, A; Concas, L; Davì, MV; de Braud, F; De Divitiis, C; Delle Fave, G; Di Costanzo, F; Di Maio, M; Duro, M; Ermacora, P; Faggiano, A; Fazio, N; Femia, D; Fontana, A; Garattini, SK; Giacomelli, L; Giuffrida, D; Ibrahim, T; La Salvia, A; Lo Russo, G; Marconcini, R; Massironi, S; Mazzaferro, V; Milione, M; Ortolani, S; Panzuto, F; Perfetti, V; Prinzi, N; Puliafito, I; Pusceddu, S; Razzore, P; Ricci, S; Rinzivillo, M; Spada, F; Tafuto, S; Torniai, M; Vernieri, C; Zaniboni, A, 2018) |
"In this study, the human pancreatic cancer cell line MiaPaca-2 was incubated with liraglutide and/or metformin." | 1.48 | Synergistic anti-tumor effects of liraglutide with metformin on pancreatic cancer cells. ( Hong, T; Ke, J; Liu, J; Lu, R; Tian, Q; Wei, R; Yang, J; Yu, F; Zhang, J, 2018) |
"Treatment with metformin also suppressed tumor growth, invasion and EMT in LSL‑KrasG12D/+, Trp53fl/+and Pdx1‑Cre (KPC) transgenic mice that harbor spontaneous pancreatic cancer." | 1.48 | Metformin suppresses the invasive ability of pancreatic cancer cells by blocking autocrine TGF‑β1 signaling. ( Cao, J; Chen, K; Cheng, L; Duan, W; Li, J; Li, X; Ma, J; Ma, Q; Qian, W; Qin, T; Xiao, Y; Zhou, C, 2018) |
"Hypoglycemia is associated with local invasion and angiogenesis, whereas hyperglycemia promotes metastatic colonization." | 1.48 | Glycemic Variability Promotes Both Local Invasion and Metastatic Colonization by Pancreatic Ductal Adenocarcinoma. ( Akkan, J; Benitz, S; Bruns, P; Ceyhan, GO; Cheng, T; Friess, H; Hofmann, T; Huang, P; Jäger, C; Jastroch, M; Jian, Z; Kleeff, J; Kleigrewe, K; Kong, B; Lamp, D; Maeritz, N; Michalski, CW; Nie, S; Raulefs, S; Shen, S; Shi, K; Steiger, K; Zhang, Z; Zou, X, 2018) |
" However, at typical antidiabetic doses the bioavailability of metformin is presumably too low to exert antitumor effects." | 1.46 | Modified Metformin as a More Potent Anticancer Drug: Mitochondrial Inhibition, Redox Signaling, Antiproliferative Effects and Future EPR Studies. ( Cheng, G; Dwinell, MB; Hardy, M; Kalyanaraman, B; Ouari, O; Sikora, A; Zielonka, J, 2017) |
"Metformin treatment itself conferred better OS in comparison within DM patients (HR 0." | 1.43 | The Impact of Diabetes Mellitus and Metformin Treatment on Survival of Patients with Advanced Pancreatic Cancer Undergoing Chemotherapy. ( Bang, YJ; Choi, Y; Han, SW; Im, SA; Kim, TY; Lee, KH; Oh, DY, 2016) |
"Metformin use was also associated with better OS (P = 0." | 1.43 | Statin and Metformin Use Prolongs Survival in Patients With Resectable Pancreatic Cancer. ( Anderson, EM; Chang, DT; Koong, AC; Kozak, MM; Norton, JA; Pai, JS; Poultsides, GA; Visser, BC; von Eyben, R, 2016) |
"We used the human pancreatic cancer cell lines Panc1, PK1 and PK9 to study the effects of metformin on human pancreatic cancer cells." | 1.43 | The anti-diabetic drug metformin inhibits pancreatic cancer cell proliferation in vitro and in vivo: Study of the microRNAs associated with the antitumor effect of metformin. ( Fujihara, S; Fujimori, T; Iwama, H; Kamada, H; Kato, K; Kobara, H; Kobayashi, K; Masaki, T; Yamashita, T, 2016) |
"Aspc1, Bxpc3 and Panc1 pancreatic cancer cells were cultured in stem cell culture medium (serum-free Dulbecco's modified Eagle medium/Nutrient Mixture F-12 containing basic fibroblast growth factor, epidermal growth factor, B27 and insulin) for 5 days and it was found that all the pancreatic cancer cells aggregated into spheres and expressed pancreatic cancer stem cell surface markers." | 1.43 | Bulk pancreatic cancer cells can convert into cancer stem cells(CSCs) in vitro and 2 compounds can target these CSCs. ( Ben, Q; Du, Y; Gao, J; Gong, Y; He, X; Huang, L; Jin, J; Li, Z; Man, X; Ning, X; Wu, H; Xu, M, 2016) |
"Although obesity is associated with increased systemic levels of placental growth factor (PlGF), the role of PlGF in obesity-induced tumor progression is not known." | 1.43 | PlGF/VEGFR-1 Signaling Promotes Macrophage Polarization and Accelerated Tumor Progression in Obesity. ( Ancukiewicz, M; Babykutty, S; Batista, A; Carmeliet, P; Chin, SM; Duda, DG; Fukumura, D; Hato, T; Hoffmman, U; Incio, J; Jain, RK; Jung, K; Khachatryan, A; Krop, IE; Ligibel, JA; McManus, DT; Puchner, SB; Rahbari, NN; Schlett, CL; Shibuya, M; Soares, R; Suboj, P; Tam, J; Vardam, TD, 2016) |
"Metformin (Met) is an approved antidiabetic drug currently being explored for repurposing in cancer treatment based on recent evidence of its apparent chemopreventive properties." | 1.43 | Mitochondria-Targeted Analogues of Metformin Exhibit Enhanced Antiproliferative and Radiosensitizing Effects in Pancreatic Cancer Cells. ( Barrios, CS; Boyle, K; Cheng, G; Dwinell, MB; Hardy, M; Johnson, BD; Kalyanaraman, B; Lopez, M; McAllister, D; Ouari, O; Weber, JJ; Zielonka, J, 2016) |
"Metformin use was identified in 456 patients (13." | 1.43 | Metformin Use Is Associated with Improved Survival in Patients Undergoing Resection for Pancreatic Cancer. ( Canner, J; Cerullo, M; Chen, SY; Gani, F; Pawlik, TM, 2016) |
"Metformin is a commonly prescribed biguanide oral hypoglycemic used for the treatment of type II DM." | 1.43 | Metformin Improves Survival in Patients with Pancreatic Ductal Adenocarcinoma and Pre-Existing Diabetes: A Propensity Score Analysis. ( Amin, S; Aronson, A; Boffetta, P; Lin, J; Lucas, AL; Mhango, G; Wisnivesky, J, 2016) |
" The present study assessed the ability of MET, alone or in combination with gemcitabine (GEM), to inhibit the growth of the human CFPAC‑1 pancreatic cancer cell line in vitro and in vivo." | 1.43 | Inhibitory effect of metformin combined with gemcitabine on pancreatic cancer cells in vitro and in vivo. ( He, Z; Jia, Z; Shi, Y; Xu, C, 2016) |
"Pancreatic cancer is one of the hardest-to-treat types of neoplastic diseases." | 1.43 | Mitochondrial Targeting of Metformin Enhances Its Activity against Pancreatic Cancer. ( Bezawork-Geleta, A; Boukalova, S; Cerny, J; Dong, L; Drahota, Z; Ezrova, Z; Neuzil, J; Pecinova, A; Stursa, J; Werner, L, 2016) |
"Metformin has been associated with reduced risk of certain cancers, including PC, in some observational clinical studies." | 1.42 | Metformin use among type 2 diabetics and risk of pancreatic cancer in a clinic-based case-control study. ( Bracci, PM; Holly, EA; Ko, AH; Walker, EJ, 2015) |
"Metformin was found to be a useful sensitising agent towards GEM treatment following gain of chemoresistance." | 1.42 | Resistance to gemcitabine in the pancreatic cancer cell line KLM1-R reversed by metformin action. ( Baron, B; Kuramitsu, Y; Maehara, S; Maehara, Y; Nakamura, K; Wang, Y, 2015) |
"Metformin may inhibit pancreatic tumorigenesis by modulating multiple molecular targets in inflammatory pathways." | 1.42 | Metformin suppresses pancreatic tumor growth with inhibition of NFκB/STAT3 inflammatory signaling. ( Bamlet, WR; Bhattacharyya, KK; Dutta, SK; Mukhopadhyay, D; Oberg, AL; Petersen, GM; Rabe, KG; Smyrk, TC; Tan, XL; Wang, E, 2015) |
"Metformin is a widely used drug for type-2 diabetes, and is also known as a promising candidate anti-cancer agent from recent studies in vitro and in vivo." | 1.42 | Metformin Causes G1-Phase Arrest via Down-Regulation of MiR-221 and Enhances TRAIL Sensitivity through DR5 Up-Regulation in Pancreatic Cancer Cells. ( Horinaka, M; Sakai, T; Sowa, Y; Tanaka, R; Tomosugi, M, 2015) |
"Metformin and aspirin have been studied extensively as cancer preventive or therapeutic agents." | 1.42 | Metformin combined with aspirin significantly inhibit pancreatic cancer cell growth in vitro and in vivo by suppressing anti-apoptotic proteins Mcl-1 and Bcl-2. ( Carpizo, D; DiPaola, RS; Huang, H; Lin, Y; Tan, XL; Xu, Q; Yang, CS; Yue, W; Zheng, X, 2015) |
"Metformin and aspirin have been studied extensively as cancer preventative and therapeutic agents." | 1.42 | Transcriptomic analysis of pancreatic cancer cells in response to metformin and aspirin: an implication of synergy. ( DiPaola, RS; Lin, Y; Tan, XL; Wang, T; Xu, Q; Yang, CS; Yue, W; Zachariah, E, 2015) |
"The association of pancreatic cancer and diabetes mellitus is explored in our study." | 1.42 | Combination of Anti-Diabetic Drug Metformin and Boswellic Acid Nanoparticles: A Novel Strategy for Pancreatic Cancer Therapy. ( Kamath, CR; Lakshmanan, VK; Nair, RS; Nair, SV; Snima, KS, 2015) |
"The prognosis of pancreatic cancer remains dismal, with little advance in chemotherapy because of its high frequency of chemoresistance." | 1.42 | Metformin Increases Sensitivity of Pancreatic Cancer Cells to Gemcitabine by Reducing CD133+ Cell Populations and Suppressing ERK/P70S6K Signaling. ( Chai, X; Chu, H; Gou, S; Meng, Y; Shi, P; Yang, X, 2015) |
"Associations between type 2 diabetes, anti-diabetic medications and pancreatic cancer are controversial." | 1.42 | New-onset type 2 diabetes, elevated HbA1c, anti-diabetic medications, and risk of pancreatic cancer. ( Bexelius, TS; García Rodríguez, LA; González-Pérez, A; Lagergren, J; Lu, Y; Malgerud, L; Martín-Pérez, M, 2015) |
"Metformin is a widely used glucose-lowering drug." | 1.42 | Metformin Reduces Desmoplasia in Pancreatic Cancer by Reprogramming Stellate Cells and Tumor-Associated Macrophages. ( Babykutty, S; Chen, I; Chin, SM; Deshpande, V; Fukumura, D; Hato, T; Incio, J; Jain, RK; Liu, H; Suboj, P; Vardam-Kaur, T, 2015) |
"Metformin is a target therapy that increases median overall survival but is not a radiation sensitizer in patients with pancreatic cancer who present with diabetes." | 1.40 | Diabetes and pancreatic cancer. ( De Souza, AL; Saif, MW, 2014) |
"Metformin use has previously been associated with decreased cancer risk." | 1.40 | Metformin suppresses sonic hedgehog expression in pancreatic cancer cells. ( Nakamura, M; Nakashima, H; Ogo, A; Yamaguchi, Y; Yamura, M, 2014) |
"The most glycolytic pancreatic cancer cell line was exquisitely sensitive to 2-DG, whereas the least glycolytic pancreatic cancer cell was resistant to 2-DG." | 1.40 | Profiling and targeting of cellular bioenergetics: inhibition of pancreatic cancer cell proliferation. ( Cheng, G; Dwinell, MB; Kalyanaraman, B; McAllister, D; Tsai, S; Zielonka, J, 2014) |
"In addition, we found that pancreatic cancer stem cell-like cells showed enhanced radiosensitization in a tumorsphere assay with a REF of 1." | 1.40 | Radiosensitization of pancreatic cancer cells by metformin through the AMPK pathway. ( Elbaz, HA; Fasih, A; Hüttemann, M; Konski, AA; Zielske, SP, 2014) |
"Treatment with metformin or down-regulation of Sp TFs by RNAi also inhibits two major pro-oncogenic pathways in pancreatic cancer cells, namely mammalian target of rapamycin (mTOR) signaling and epidermal growth factor (EGFR)-dependent activation of Ras." | 1.40 | Mechanism of metformin-dependent inhibition of mammalian target of rapamycin (mTOR) and Ras activity in pancreatic cancer: role of specificity protein (Sp) transcription factors. ( Abdelrahim, M; Abudayyeh, A; Basha, R; Nair, V; Rodrigues Hoffman, A; Safe, S; Sreevalsan, S, 2014) |
"Metformin also inhibited the growth of pancreatic cancer xenografts when administered orally (2." | 1.39 | Metformin inhibits the growth of human pancreatic cancer xenografts. ( Eibl, G; Kisfalvi, K; Moro, A; Rozengurt, E; Sinnett-Smith, J, 2013) |
"Up to 80% of pancreatic cancer patients present with either new-onset type 2 diabetes or impaired glucose tolerance at the time of diagnosis." | 1.39 | Metformin-mediated growth inhibition involves suppression of the IGF-I receptor signalling pathway in human pancreatic cancer cells. ( Andersson, R; Karnevi, E; Rosendahl, AH; Said, K, 2013) |
"Metformin is a drug widely used for the treatment of type II diabetes." | 1.39 | Low concentrations of metformin selectively inhibit CD133⁺ cell proliferation in pancreatic cancer and have anticancer action. ( Cui, P; Gou, S; Li, X; Liu, T; Shi, P; Wang, C, 2013) |
"Metformin treatment alone or with sitagliptin decreased islet amyloid deposition to a similar extent vs untreated mice." | 1.39 | One year of sitagliptin treatment protects against islet amyloid-associated β-cell loss and does not induce pancreatitis or pancreatic neoplasia in mice. ( Aston-Mourney, K; Goldstein, LC; Hull, RL; Meier, DT; Samarasekera, T; Subramanian, SL; Zraika, S, 2013) |
"Metformin is a widely used antidiabetic drug, and epidemiology studies for pancreatic and other cancers indicate that metformin exhibits both chemopreventive and chemotherapeutic activities." | 1.39 | Metformin inhibits pancreatic cancer cell and tumor growth and downregulates Sp transcription factors. ( Abdelrahim, M; Basha, R; Jutooru, I; Nair, V; Pathi, S; Safe, S; Samudio, I; Sreevalsan, S, 2013) |
"Pancreatic cancer is the fourth leading cause of cancer-related deaths in the United States, which is, in part, due to intrinsic (de novo) and extrinsic (acquired) resistance to conventional therapeutics, suggesting that innovative treatment strategies are required for overcoming therapeutic resistance to improve overall survival of patients." | 1.38 | Metformin inhibits cell proliferation, migration and invasion by attenuating CSC function mediated by deregulating miRNAs in pancreatic cancer cells. ( Ahmad, A; Ali, S; Azmi, AS; Banerjee, S; Bao, B; Kong, D; Li, Y; Sarkar, FH; Sarkar, SH; Thakur, S; Wang, Z, 2012) |
"Type 2 diabetes mellitus is likely the third modifiable risk factor for pancreatic cancer after cigarette smoking and obesity." | 1.38 | Diabetes and pancreatic cancer. ( Li, D, 2012) |
"Pancreatic cancer is a disease with a dismal prognosis and treatment options are limited." | 1.38 | A humanized anti-IGF-1R monoclonal antibody (R1507) and/or metformin enhance gemcitabine-induced apoptosis in pancreatic cancer cells. ( Funakoshi, A; Ikeda, N; Kawanami, T; Takiguchi, S, 2012) |
"Metformin use was significantly associated with longer survival in patients with nonmetastatic disease only." | 1.38 | Metformin use is associated with better survival of diabetic patients with pancreatic cancer. ( Abbruzzese, JL; Hassan, M; Li, D; Sadeghi, N; Yeung, SC, 2012) |
"Metformin and rosiglitazone suppressed cancer cell growth and induced apoptosis." | 1.37 | The impact of type 2 diabetes and antidiabetic drugs on cancer cell growth. ( Chen, J; Feng, YH; Gully, C; Lee, MH; Velazquez-Torres, G; Yeung, SC, 2011) |
" The covariates included age, gender, other oral anti-hyperglycemic medication, Charlson comorbidity index (CCI) score and metformin exposure dosage and duration." | 1.37 | Type 2 diabetes increases and metformin reduces total, colorectal, liver and pancreatic cancer incidences in Taiwanese: a representative population prospective cohort study of 800,000 individuals. ( Chang, YH; Hsu, CC; Huang, YC; Lee, MS; Tsai, HN; Wahlqvist, ML, 2011) |
"Novel targets for pancreatic cancer therapy are urgently needed." | 1.36 | Crosstalk between insulin/insulin-like growth factor-1 receptors and G protein-coupled receptor signaling systems: a novel target for the antidiabetic drug metformin in pancreatic cancer. ( Kisfalvi, K; Rozengurt, E; Sinnett-Smith, J, 2010) |
"The human pancreatic cancer cell lines ASPC-1, BxPc-3, PANC-1 and SW1990 were exposed to metformin." | 1.35 | Metformin induces apoptosis of pancreatic cancer cells. ( Gao, J; Jin, ZD; Li, ZS; Wang, LW; Xu, GM; Zou, DW, 2008) |
"Metformin use was associated with reduced risk, and insulin or insulin secretagogue use was associated with increased risk of pancreatic cancer in diabetic patients." | 1.35 | Antidiabetic therapies affect risk of pancreatic cancer. ( Abbruzzese, JL; Hassan, MM; Konopleva, M; Li, D; Yeung, SC, 2009) |
"Metformin pretreatment completely abrogated insulin-induced potentiation of Ca(2+) signaling but did not interfere with the effect of GPCR agonists alone." | 1.35 | Metformin disrupts crosstalk between G protein-coupled receptor and insulin receptor signaling systems and inhibits pancreatic cancer growth. ( Eibl, G; Kisfalvi, K; Rozengurt, E; Sinnett-Smith, J, 2009) |
Research
Studies (182)
Timeframe | Studies, this research(%) | All Research% |
---|---|---|
pre-1990 | 0 (0.00) | 18.7374 |
1990's | 0 (0.00) | 18.2507 |
2000's | 4 (2.20) | 29.6817 |
2010's | 138 (75.82) | 24.3611 |
2020's | 40 (21.98) | 2.80 |
Authors
Authors | Studies |
---|---|
Xue, D | 1 |
Xu, Y | 1 |
Kyani, A | 1 |
Roy, J | 1 |
Dai, L | 1 |
Sun, D | 1 |
Neamati, N | 1 |
Shi, L | 1 |
Wen, J | 1 |
Zhang, W | 1 |
Meng, FD | 1 |
Wan, Y | 1 |
Wang, L | 1 |
Zhang, L | 2 |
Zhu, HY | 1 |
Zhang, X | 3 |
Ogihara, T | 1 |
Zhu, M | 2 |
Gantumur, D | 1 |
Li, Y | 5 |
Mizoi, K | 1 |
Kamioka, H | 1 |
Tsushima, Y | 1 |
Zhu, D | 1 |
Xia, J | 1 |
Liu, C | 2 |
Fang, C | 1 |
Selvarajoo, N | 1 |
Stanslas, J | 1 |
Islam, MK | 1 |
Sagineedu, SR | 1 |
Lian, HK | 1 |
Lim, JCW | 1 |
Gulla, A | 1 |
Andriusaityte, U | 1 |
Zdanys, GT | 1 |
Babonaite, E | 1 |
Strupas, K | 1 |
Kelly, H | 1 |
Kurita, Y | 1 |
Kobayashi, N | 1 |
Hara, K | 1 |
Mizuno, N | 1 |
Kuwahara, T | 1 |
Okuno, N | 1 |
Haba, S | 1 |
Tokuhisa, M | 1 |
Hasegawa, S | 1 |
Sato, T | 1 |
Hosono, K | 1 |
Kato, S | 1 |
Kessoku, T | 1 |
Endo, I | 1 |
Shimizu, Y | 1 |
Kubota, K | 1 |
Nakajima, A | 1 |
Ichikawa, Y | 1 |
Niwa, Y | 1 |
Zaccari, P | 1 |
Archibugi, L | 1 |
Belfiori, G | 1 |
Nista, E | 1 |
dell'Anna, G | 1 |
Crippa, S | 1 |
Schepis, T | 1 |
Tacelli, M | 1 |
Aleotti, F | 1 |
Petrone, MC | 1 |
Mariani, A | 1 |
Costamagna, G | 1 |
Gasbarrini, A | 1 |
Larghi, A | 1 |
Falconi, M | 2 |
Arcidiacono, PG | 1 |
Capurso, G | 1 |
d'Hose, D | 1 |
Mathieu, B | 1 |
Mignion, L | 1 |
Hardy, M | 3 |
Ouari, O | 3 |
Jordan, BF | 1 |
Sonveaux, P | 1 |
Gallez, B | 1 |
Scarton, L | 1 |
Jo, A | 1 |
Xie, Z | 1 |
O'Neal, LJ | 1 |
Munoz Pena, JM | 1 |
George, TJ | 1 |
Bian, J | 1 |
Han, P | 1 |
Zhou, J | 1 |
Xiang, J | 1 |
Liu, Q | 1 |
Sun, K | 1 |
Pretta, A | 2 |
Ziranu, P | 2 |
Giampieri, R | 2 |
Donisi, C | 2 |
Cimbro, E | 2 |
Spanu, D | 2 |
Lai, E | 2 |
Pecci, F | 2 |
Balconi, F | 2 |
Lupi, A | 2 |
Pozzari, M | 2 |
Persano, M | 2 |
Murgia, S | 2 |
Pusceddu, V | 2 |
Puzzoni, M | 2 |
Berardi, R | 3 |
Scartozzi, M | 2 |
Abdelmoneim, M | 2 |
Eissa, IR | 2 |
Aboalela, MA | 2 |
Naoe, Y | 2 |
Matsumura, S | 3 |
Sibal, PA | 2 |
Bustos-Villalobos, I | 2 |
Tanaka, M | 2 |
Kodera, Y | 2 |
Kasuya, H | 2 |
Nowicka, Z | 1 |
Matyjek, A | 1 |
Płoszka, K | 1 |
Łaszczych, M | 1 |
Fendler, W | 1 |
Hu, J | 1 |
Fan, HD | 1 |
Gong, JP | 1 |
Mao, QS | 1 |
Wang, G | 1 |
Gao, H | 1 |
Dai, S | 1 |
Li, M | 1 |
Gao, Y | 1 |
Yin, L | 1 |
Zhang, K | 1 |
Zhang, J | 2 |
Jiang, K | 1 |
Miao, Y | 1 |
Lu, Z | 1 |
Agay, N | 1 |
Dankner, R | 2 |
Murad, H | 1 |
Olmer, L | 1 |
Freedman, LS | 1 |
Hamano, K | 1 |
Akita, K | 1 |
Takeuchi, Y | 1 |
Suwa, T | 1 |
Takeda, J | 1 |
Dodo, S | 1 |
Toriola, AT | 1 |
Luo, S | 1 |
Thomas, TS | 1 |
Drake, BF | 1 |
Chang, SH | 1 |
Sanfilippo, KM | 1 |
Carson, KR | 1 |
Roth, J | 1 |
de Mestier, L | 1 |
Védie, AL | 1 |
Faron, M | 1 |
Cros, J | 1 |
Rebours, V | 1 |
Hentic, O | 1 |
Do Cao, C | 1 |
Bardet, P | 1 |
Lévy, P | 1 |
Sauvanet, A | 1 |
Ruszniewski, P | 1 |
Hammel, P | 1 |
Deschênes-Simard, X | 1 |
Rowell, MC | 1 |
Ferbeyre, G | 1 |
Zhou, HY | 1 |
Yao, XM | 1 |
Chen, XD | 1 |
Tang, JM | 1 |
Qiao, ZG | 1 |
Wu, XY | 1 |
Yamana, H | 1 |
Kato, K | 2 |
Kobara, H | 2 |
Fujihara, S | 2 |
Fujita, K | 1 |
Namima, D | 1 |
Fujita, N | 1 |
Kobayashi, K | 2 |
Kamada, H | 2 |
Morishita, A | 1 |
Tsutsui, K | 1 |
Iwama, H | 2 |
Masaki, T | 2 |
Wendt, EHU | 1 |
Schoenrogge, M | 1 |
Vollmar, B | 4 |
Zechner, D | 4 |
Han, H | 1 |
Hou, Y | 1 |
Chen, X | 2 |
Zhang, P | 1 |
Kang, M | 1 |
Jin, Q | 1 |
Ji, J | 1 |
Gao, M | 1 |
Broadhurst, PJ | 2 |
Hart, AR | 2 |
Vitali, E | 1 |
Boemi, I | 1 |
Piccini, S | 1 |
Tarantola, G | 1 |
Smiroldo, V | 1 |
Lavezzi, E | 1 |
Brambilla, T | 1 |
Zerbi, A | 1 |
Carnaghi, C | 2 |
Mantovani, G | 1 |
Spada, A | 1 |
Lania, AG | 1 |
Terasaki, F | 1 |
Sugiura, T | 1 |
Okamura, Y | 1 |
Ito, T | 1 |
Yamamoto, Y | 1 |
Ashida, R | 1 |
Ohgi, K | 1 |
Uesaka, K | 1 |
Alcalá, S | 1 |
Sancho, P | 5 |
Martinelli, P | 2 |
Navarro, D | 1 |
Pedrero, C | 1 |
Martín-Hijano, L | 1 |
Valle, S | 1 |
Earl, J | 1 |
Rodríguez-Serrano, M | 1 |
Ruiz-Cañas, L | 1 |
Rojas, K | 1 |
Carrato, A | 1 |
García-Bermejo, L | 1 |
Fernández-Moreno, MÁ | 1 |
Hermann, PC | 2 |
Sainz, B | 3 |
Zhao, HW | 1 |
Zhou, N | 1 |
Jin, F | 1 |
Wang, R | 1 |
Zhao, JQ | 1 |
Fan, Z | 1 |
Gong, Y | 2 |
Huang, Q | 2 |
Yang, C | 1 |
Cheng, H | 1 |
Jin, K | 1 |
Fan, K | 1 |
Ni, Q | 1 |
Yu, X | 2 |
Luo, G | 1 |
Yoshida, J | 1 |
Ishikawa, T | 1 |
Endo, Y | 1 |
Ota, T | 1 |
Mizushima, K | 1 |
Hirai, Y | 1 |
Oka, K | 1 |
Okayama, T | 1 |
Sakamoto, N | 1 |
Inoue, K | 1 |
Kamada, K | 1 |
Uchiyama, K | 1 |
Takagi, T | 1 |
Naito, Y | 1 |
Itoh, Y | 1 |
Ma, M | 1 |
Ma, C | 2 |
Li, P | 1 |
Ping, F | 1 |
Li, W | 2 |
Xu, L | 2 |
Zhang, H | 1 |
Sun, Q | 2 |
Wang, C | 3 |
Zhang, T | 1 |
Liao, Q | 1 |
Dai, M | 1 |
Guo, J | 2 |
Yang, X | 2 |
Tan, W | 1 |
Lin, D | 1 |
Wu, C | 1 |
Zhao, Y | 1 |
Liu, SH | 2 |
Yu, J | 2 |
Creeden, JF | 1 |
Sutton, JM | 1 |
Markowiak, S | 1 |
Sanchez, R | 2 |
Nemunaitis, J | 2 |
Kalinoski, A | 1 |
Zhang, JT | 1 |
Damoiseaux, R | 1 |
Erhardt, P | 1 |
Brunicardi, FC | 2 |
Shi, YQ | 1 |
Zhou, XC | 1 |
Du, P | 1 |
Yin, MY | 1 |
Chen, WJ | 1 |
Xu, CF | 1 |
Farag, MM | 1 |
Abd El Malak, NS | 1 |
Yehia, SA | 1 |
Ahmed, MA | 1 |
Eyres, M | 1 |
Lanfredini, S | 1 |
Xu, H | 1 |
Burns, A | 1 |
Blake, A | 1 |
Willenbrock, F | 1 |
Goldin, R | 1 |
Hughes, D | 1 |
Hughes, S | 1 |
Thapa, A | 1 |
Vavoulis, D | 1 |
Hubert, A | 1 |
D'Costa, Z | 1 |
Sabbagh, A | 1 |
Abraham, AG | 1 |
Blancher, C | 1 |
Jones, S | 1 |
Verrill, C | 1 |
Silva, M | 1 |
Soonawalla, Z | 1 |
Maughan, T | 1 |
Schuh, A | 1 |
Mukherjee, S | 1 |
O'Neill, E | 1 |
Abrams, SL | 3 |
Akula, SM | 2 |
Meher, AK | 1 |
Steelman, LS | 2 |
Gizak, A | 3 |
Duda, P | 1 |
Rakus, D | 3 |
Martelli, AM | 3 |
Ratti, S | 3 |
Cocco, L | 2 |
Montalto, G | 3 |
Cervello, M | 3 |
Ruvolo, P | 1 |
Libra, M | 3 |
Falzone, L | 1 |
Candido, S | 3 |
McCubrey, JA | 3 |
Eibl, G | 5 |
Rozengurt, E | 9 |
Støer, NC | 1 |
Bouche, G | 1 |
Pantziarka, P | 1 |
Sloan, EK | 1 |
Andreassen, BK | 1 |
Botteri, E | 1 |
Wu, BU | 1 |
Graber, JM | 2 |
Lu, SE | 2 |
Lin, Y | 4 |
Lu-Yao, G | 2 |
Tan, XL | 6 |
Kalyanaraman, B | 3 |
Cheng, G | 3 |
Sikora, A | 1 |
Zielonka, J | 3 |
Dwinell, MB | 3 |
Zhou, PT | 1 |
Li, B | 1 |
Liu, FR | 1 |
Zhang, MC | 1 |
Wang, Q | 1 |
Li, YY | 1 |
Xu, C | 2 |
Liu, YH | 1 |
Yao, Y | 1 |
Li, D | 5 |
E, JY | 1 |
Rotter, D | 1 |
Petersen, GM | 3 |
Demissie, K | 1 |
Li, X | 4 |
Li, T | 1 |
Liu, Z | 1 |
Gou, S | 3 |
Chen, K | 4 |
Qian, W | 3 |
Jiang, Z | 3 |
Cheng, L | 3 |
Li, J | 6 |
Sun, L | 2 |
Zhou, C | 4 |
Gao, L | 1 |
Lei, M | 1 |
Yan, B | 2 |
Cao, J | 3 |
Duan, W | 4 |
Ma, Q | 4 |
Li, L | 1 |
Zhang, G | 1 |
Wang, Y | 2 |
Chen, H | 1 |
Kong, R | 1 |
Pan, S | 1 |
Sun, B | 1 |
Safe, S | 3 |
Nair, V | 3 |
Karki, K | 1 |
Goldenberg, JM | 1 |
Cárdenas-Rodríguez, J | 1 |
Pagel, MD | 1 |
Sun, H | 1 |
Zheng, C | 1 |
Gao, J | 3 |
Fu, Q | 1 |
Hu, N | 1 |
Shao, X | 1 |
Zhou, Y | 1 |
Xiong, J | 1 |
Nie, K | 1 |
Zhou, H | 1 |
Shen, L | 1 |
Fang, H | 1 |
Lyu, J | 1 |
Wirunsawanya, K | 1 |
Jaruvongvanich, V | 1 |
Upala, S | 1 |
Steelman, L | 1 |
Lertpiriyapong, K | 2 |
Follo, MY | 2 |
Murata, RM | 2 |
Rosalen, PL | 2 |
Lombardi, P | 2 |
Suh, PG | 1 |
Song, L | 1 |
Chang, R | 1 |
Peng, X | 1 |
Xu, X | 1 |
Zhan, X | 1 |
Zhan, L | 1 |
Schönrogge, M | 2 |
Kerndl, H | 1 |
Kumstel, S | 2 |
Chang, HH | 1 |
Moro, A | 2 |
Chou, CEN | 1 |
Dawson, DW | 1 |
French, S | 1 |
Schmidt, AI | 1 |
Sinnett-Smith, J | 8 |
Hao, F | 1 |
Hines, OJ | 1 |
Pusceddu, S | 2 |
Vernieri, C | 2 |
Di Maio, M | 1 |
Marconcini, R | 1 |
Spada, F | 1 |
Massironi, S | 1 |
Ibrahim, T | 1 |
Brizzi, MP | 1 |
Campana, D | 1 |
Faggiano, A | 1 |
Giuffrida, D | 1 |
Rinzivillo, M | 1 |
Cingarlini, S | 1 |
Aroldi, F | 1 |
Antonuzzo, L | 1 |
Catena, L | 1 |
De Divitiis, C | 1 |
Ermacora, P | 1 |
Perfetti, V | 1 |
Fontana, A | 1 |
Razzore, P | 1 |
Davì, MV | 1 |
Cauchi, C | 1 |
Duro, M | 1 |
Ricci, S | 1 |
Fazio, N | 1 |
Cavalcoli, F | 1 |
Bongiovanni, A | 1 |
La Salvia, A | 1 |
Brighi, N | 1 |
Colao, A | 1 |
Puliafito, I | 1 |
Panzuto, F | 1 |
Ortolani, S | 1 |
Zaniboni, A | 1 |
Di Costanzo, F | 1 |
Torniai, M | 1 |
Bajetta, E | 1 |
Tafuto, S | 1 |
Garattini, SK | 1 |
Femia, D | 2 |
Prinzi, N | 1 |
Concas, L | 2 |
Lo Russo, G | 1 |
Milione, M | 2 |
Giacomelli, L | 2 |
Buzzoni, R | 2 |
Delle Fave, G | 1 |
Mazzaferro, V | 2 |
de Braud, F | 2 |
Lu, R | 1 |
Yang, J | 1 |
Wei, R | 1 |
Ke, J | 1 |
Tian, Q | 1 |
Yu, F | 1 |
Liu, J | 2 |
Hong, T | 1 |
Lee, DY | 1 |
Yu, JH | 1 |
Park, S | 1 |
Han, K | 1 |
Kim, NH | 2 |
Yoo, HJ | 1 |
Choi, KM | 1 |
Baik, SH | 1 |
Seo, JA | 1 |
Qin, T | 1 |
Xiao, Y | 1 |
Ma, J | 2 |
Kubo, T | 1 |
Ninomiya, T | 1 |
Hotta, K | 1 |
Kozuki, T | 1 |
Toyooka, S | 1 |
Okada, H | 1 |
Fujiwara, T | 1 |
Udono, H | 1 |
Kiura, K | 1 |
Wan, G | 1 |
Sun, X | 1 |
Li, F | 1 |
Wang, X | 3 |
Li, C | 1 |
Li, H | 1 |
Cao, F | 1 |
Tseng, CH | 1 |
Jian, Z | 1 |
Cheng, T | 1 |
Zhang, Z | 1 |
Raulefs, S | 1 |
Shi, K | 1 |
Steiger, K | 1 |
Maeritz, N | 1 |
Kleigrewe, K | 1 |
Hofmann, T | 1 |
Benitz, S | 1 |
Bruns, P | 1 |
Lamp, D | 1 |
Jastroch, M | 1 |
Akkan, J | 1 |
Jäger, C | 1 |
Huang, P | 1 |
Nie, S | 1 |
Shen, S | 1 |
Zou, X | 1 |
Ceyhan, GO | 1 |
Michalski, CW | 1 |
Friess, H | 1 |
Kleeff, J | 1 |
Kong, B | 1 |
Montvida, O | 1 |
Green, JB | 1 |
Atherton, J | 1 |
Paul, SK | 1 |
Suzuki, K | 1 |
Takeuchi, O | 1 |
Suzuki, Y | 1 |
Kitagawa, Y | 1 |
Wei, M | 1 |
Liu, Y | 4 |
Bi, Y | 1 |
Zhang, ZJ | 1 |
Lai, SW | 1 |
Tsai, CH | 1 |
Lin, CL | 1 |
Liao, KF | 1 |
Ramazzotti, G | 1 |
Bueno-Silva, B | 1 |
Matias de Alencar, S | 1 |
Mao, W | 1 |
Lin, HL | 1 |
Cho, J | 1 |
Scragg, R | 1 |
Pandol, SJ | 1 |
Goodarzi, MO | 1 |
Petrov, MS | 1 |
Wynn, A | 1 |
Vacheron, A | 1 |
Zuber, J | 1 |
Solomon, SS | 1 |
Andersen, DK | 4 |
Soares, HP | 2 |
Ni, Y | 1 |
Kisfalvi, K | 5 |
Karnevi, E | 2 |
Said, K | 1 |
Andersson, R | 2 |
Rosendahl, AH | 2 |
Cui, P | 1 |
Shi, P | 2 |
Liu, T | 1 |
Aston-Mourney, K | 1 |
Subramanian, SL | 1 |
Zraika, S | 1 |
Samarasekera, T | 1 |
Meier, DT | 1 |
Goldstein, LC | 1 |
Hull, RL | 1 |
Pathi, S | 1 |
Jutooru, I | 1 |
Sreevalsan, S | 2 |
Basha, R | 2 |
Abdelrahim, M | 2 |
Samudio, I | 1 |
El-Jurdi, NH | 1 |
Saif, MW | 5 |
Hwang, AL | 1 |
Haynes, K | 1 |
Hwang, WT | 1 |
Yang, YX | 2 |
Funch, D | 1 |
Gydesen, H | 1 |
Tornøe, K | 1 |
Major-Pedersen, A | 1 |
Chan, KA | 1 |
Lonardo, E | 2 |
Cioffi, M | 2 |
Sanchez-Ripoll, Y | 1 |
Trabulo, SM | 1 |
Dorado, J | 1 |
Balic, A | 1 |
Hidalgo, M | 1 |
Heeschen, C | 4 |
Yue, W | 3 |
Yang, CS | 3 |
DiPaola, RS | 3 |
Gionfriddo, MR | 1 |
Morey-Vargas, OL | 1 |
Brito, JP | 1 |
Leppin, AL | 1 |
Murad, MH | 2 |
Montori, VM | 1 |
De Souza, AL | 1 |
Nakamura, M | 1 |
Ogo, A | 1 |
Yamura, M | 1 |
Yamaguchi, Y | 1 |
Nakashima, H | 1 |
Snima, KS | 3 |
Jayakumar, R | 2 |
Unnikrishnan, AG | 1 |
Nair, SV | 2 |
Lakshmanan, VK | 3 |
Wang, Z | 4 |
Lai, ST | 2 |
Xie, L | 1 |
Zhao, JD | 2 |
Ma, NY | 2 |
Zhu, J | 1 |
Ren, ZG | 1 |
Jiang, GL | 2 |
McAllister, D | 2 |
Tsai, S | 1 |
Simon-Szabó, L | 1 |
Kokas, M | 1 |
Mandl, J | 1 |
Kéri, G | 1 |
Csala, M | 1 |
Fasih, A | 1 |
Elbaz, HA | 1 |
Hüttemann, M | 1 |
Konski, AA | 1 |
Zielske, SP | 1 |
Yoon, JW | 1 |
Jung, HS | 1 |
Jang, JY | 1 |
Kim, MJ | 1 |
Kim, JH | 2 |
Ohn, JH | 1 |
Lee, HM | 1 |
Kim, HC | 1 |
Lee, KB | 1 |
Choi, SA | 1 |
Kim, SW | 1 |
Park, KS | 1 |
Burney, S | 1 |
Khawaja, KI | 2 |
Masud, F | 2 |
Kaddis, N | 1 |
Walker, EJ | 1 |
Ko, AH | 1 |
Holly, EA | 1 |
Bracci, PM | 1 |
Cañamero, M | 1 |
Madriles, F | 1 |
Michl, P | 1 |
Gress, T | 1 |
de Pascual, R | 1 |
Gandia, L | 1 |
Guerra, C | 1 |
Barbacid, M | 1 |
Wagner, M | 1 |
Vieira, CR | 1 |
Aicher, A | 1 |
Real, FX | 1 |
Abudayyeh, A | 1 |
Rodrigues Hoffman, A | 1 |
Herrigel, DJ | 1 |
Moss, RA | 1 |
Ming, M | 1 |
Wang, J | 1 |
Young, SH | 1 |
Cifarelli, V | 1 |
Lashinger, LM | 1 |
Devlin, KL | 1 |
Dunlap, SM | 1 |
Huang, J | 1 |
Kaaks, R | 1 |
Pollak, MN | 2 |
Hursting, SD | 1 |
Choi, Y | 1 |
Kim, TY | 2 |
Oh, DY | 1 |
Lee, KH | 1 |
Han, SW | 1 |
Im, SA | 1 |
Bang, YJ | 1 |
Baron, B | 1 |
Maehara, S | 1 |
Maehara, Y | 1 |
Kuramitsu, Y | 1 |
Nakamura, K | 1 |
Bhattacharyya, KK | 1 |
Dutta, SK | 1 |
Bamlet, WR | 2 |
Rabe, KG | 1 |
Wang, E | 1 |
Smyrk, TC | 1 |
Oberg, AL | 2 |
Mukhopadhyay, D | 1 |
Radecke, T | 2 |
Amme, J | 1 |
Bürtin, F | 2 |
Albert, AC | 2 |
Partecke, LI | 1 |
Tanaka, R | 1 |
Tomosugi, M | 1 |
Horinaka, M | 1 |
Sowa, Y | 1 |
Sakai, T | 1 |
Lin, CM | 1 |
Huang, HL | 1 |
Chu, FY | 1 |
Fan, HC | 1 |
Chen, HA | 1 |
Chu, DM | 1 |
Wu, LW | 1 |
Wang, CC | 1 |
Chen, WL | 1 |
Lin, SH | 1 |
Ho, SY | 1 |
Zhang, JW | 1 |
Zheng, X | 1 |
Xu, Q | 4 |
Carpizo, D | 1 |
Huang, H | 1 |
Aung, KL | 1 |
Moore, MJ | 1 |
Kordes, S | 1 |
Zwinderman, AH | 1 |
Mathôt, RA | 1 |
Weterman, MJ | 1 |
Beeker, A | 1 |
Punt, CJ | 1 |
Richel, DJ | 1 |
Wilmink, JW | 1 |
Crusz, S | 1 |
Wang, T | 1 |
Zachariah, E | 1 |
Nair, RS | 1 |
Kamath, CR | 1 |
Deng, Y | 2 |
Wei, DP | 1 |
Burgos-Ramos, E | 1 |
Tavera, A | 1 |
Bou Kheir, T | 1 |
Jagust, P | 1 |
Schoenhals, M | 1 |
Barneda, D | 1 |
Sellers, K | 1 |
Campos-Olivas, R | 1 |
Graña, O | 1 |
Viera, CR | 1 |
Yuneva, M | 1 |
Chai, X | 1 |
Chu, H | 1 |
Meng, Y | 1 |
Chao, DT | 1 |
Shah, NH | 1 |
Zeh, HJ | 1 |
Bahary, N | 1 |
Whitcomb, DC | 1 |
Brand, RE | 1 |
Reni, M | 1 |
Dugnani, E | 1 |
Cereda, S | 1 |
Belli, C | 1 |
Balzano, G | 1 |
Nicoletti, R | 1 |
Liberati, D | 1 |
Pasquale, V | 1 |
Scavini, M | 1 |
Maggiora, P | 1 |
Sordi, V | 1 |
Lampasona, V | 1 |
Ceraulo, D | 1 |
Di Terlizzi, G | 1 |
Doglioni, C | 1 |
Piemonti, L | 1 |
Kozak, MM | 1 |
Anderson, EM | 1 |
von Eyben, R | 1 |
Pai, JS | 1 |
Poultsides, GA | 1 |
Visser, BC | 1 |
Norton, JA | 1 |
Koong, AC | 1 |
Chang, DT | 1 |
Lu, Y | 1 |
García Rodríguez, LA | 1 |
Malgerud, L | 1 |
González-Pérez, A | 1 |
Martín-Pérez, M | 1 |
Lagergren, J | 1 |
Bexelius, TS | 1 |
Rustgi, AK | 1 |
Incio, J | 2 |
Suboj, P | 2 |
Chin, SM | 2 |
Vardam-Kaur, T | 1 |
Liu, H | 1 |
Hato, T | 2 |
Babykutty, S | 2 |
Chen, I | 1 |
Deshpande, V | 1 |
Jain, RK | 2 |
Fukumura, D | 2 |
Zhou, G | 1 |
Wang, A | 1 |
Wu, J | 1 |
Ricordi, C | 1 |
Yamashita, T | 1 |
Fujimori, T | 1 |
Ning, X | 1 |
Du, Y | 1 |
Ben, Q | 1 |
Huang, L | 2 |
He, X | 1 |
Wu, H | 1 |
Man, X | 1 |
Jin, J | 1 |
Xu, M | 1 |
Li, Z | 1 |
De Souza, A | 1 |
Lipner, MB | 1 |
Marayati, R | 1 |
Raftery, L | 1 |
O'Neil, BH | 1 |
Yeh, JJ | 1 |
Lee, SH | 1 |
Yoon, SH | 1 |
Lee, HS | 1 |
Chung, MJ | 1 |
Park, JY | 1 |
Park, SW | 1 |
Song, SY | 1 |
Chung, JB | 1 |
Bang, S | 1 |
Tam, J | 1 |
Rahbari, NN | 1 |
McManus, DT | 1 |
Vardam, TD | 1 |
Batista, A | 1 |
Jung, K | 1 |
Khachatryan, A | 1 |
Ligibel, JA | 1 |
Krop, IE | 1 |
Puchner, SB | 1 |
Schlett, CL | 1 |
Hoffmman, U | 1 |
Ancukiewicz, M | 1 |
Shibuya, M | 1 |
Carmeliet, P | 1 |
Soares, R | 1 |
Duda, DG | 1 |
Marceglia, S | 1 |
Leuzzi, L | 1 |
Formisano, B | 1 |
Ambe, CM | 1 |
Mahipal, A | 1 |
Fulp, J | 1 |
Chen, L | 1 |
Malafa, MP | 1 |
Chaiteerakij, R | 1 |
Chaffee, KG | 1 |
Zhen, DB | 1 |
Burch, PA | 1 |
Leof, ER | 1 |
Roberts, LR | 1 |
Stiefelhagen, P | 1 |
Bhaw-Luximon, A | 1 |
Jhurry, D | 1 |
Lopez, M | 1 |
Boyle, K | 1 |
Barrios, CS | 1 |
Weber, JJ | 1 |
Johnson, BD | 1 |
Cerullo, M | 1 |
Gani, F | 1 |
Chen, SY | 1 |
Canner, J | 1 |
Pawlik, TM | 1 |
Elmaci, İ | 1 |
Altinoz, MA | 1 |
Amin, S | 2 |
Mhango, G | 1 |
Lin, J | 1 |
Aronson, A | 1 |
Wisnivesky, J | 1 |
Boffetta, P | 2 |
Lucas, AL | 2 |
Graffunder, J | 1 |
Shih, HY | 1 |
Müller, S | 1 |
Jaster, R | 1 |
Shi, Y | 1 |
He, Z | 1 |
Jia, Z | 1 |
Elgogary, A | 1 |
Poore, B | 1 |
Alt, J | 1 |
Zimmermann, SC | 1 |
Zhao, L | 1 |
Fu, J | 1 |
Chen, B | 1 |
Xia, S | 1 |
Neisser, M | 1 |
Nguyen, C | 1 |
Lee, R | 1 |
Park, JK | 1 |
Reyes, J | 1 |
Hartung, T | 1 |
Rojas, C | 1 |
Rais, R | 1 |
Tsukamoto, T | 1 |
Semenza, GL | 1 |
Hanes, J | 1 |
Slusher, BS | 1 |
Le, A | 1 |
Jiang, MJ | 1 |
Dai, JJ | 1 |
Gu, DN | 1 |
Tian, L | 1 |
Zhang, Q | 1 |
Kang, L | 1 |
Yang, Y | 1 |
Yang, L | 2 |
Zu, L | 1 |
Shen, Y | 1 |
Qi, Z | 1 |
Boukalova, S | 1 |
Stursa, J | 1 |
Werner, L | 1 |
Ezrova, Z | 1 |
Cerny, J | 1 |
Bezawork-Geleta, A | 1 |
Pecinova, A | 1 |
Dong, L | 1 |
Drahota, Z | 1 |
Neuzil, J | 1 |
Lei, J | 1 |
Han, L | 1 |
Wu, Z | 1 |
Wang, F | 1 |
Wu, E | 1 |
Ma, Z | 1 |
Halbrook, CJ | 1 |
Lyssiotis, CA | 1 |
Chang, VH | 1 |
Tsai, YC | 1 |
Tsai, YL | 1 |
Peng, SL | 1 |
Chen, SL | 1 |
Chang, TM | 1 |
Yu, WC | 1 |
Ch'ang, HJ | 1 |
Frouws, MA | 1 |
Sibinga Mulder, BG | 1 |
Bastiaannet, E | 1 |
Zanders, MMJ | 1 |
van Herk-Sukel, MPP | 1 |
de Leede, EM | 1 |
Bonsing, BA | 1 |
Mieog, JSD | 1 |
Van de Velde, CJH | 1 |
Liefers, GJ | 1 |
Wang, LW | 1 |
Li, ZS | 1 |
Zou, DW | 1 |
Jin, ZD | 1 |
Xu, GM | 1 |
Yeung, SC | 3 |
Hassan, MM | 1 |
Konopleva, M | 1 |
Abbruzzese, JL | 3 |
Nicolucci, A | 1 |
Feng, YH | 1 |
Velazquez-Torres, G | 1 |
Gully, C | 1 |
Chen, J | 1 |
Lee, MH | 1 |
Lee, MS | 1 |
Hsu, CC | 1 |
Wahlqvist, ML | 1 |
Tsai, HN | 1 |
Chang, YH | 1 |
Huang, YC | 1 |
Magruder, JT | 1 |
Elahi, D | 1 |
Cui, Y | 2 |
Ringel, J | 1 |
Lerch, MM | 1 |
Mayerle, J | 1 |
Bao, B | 1 |
Ali, S | 2 |
Ahmad, A | 1 |
Azmi, AS | 1 |
Sarkar, SH | 1 |
Banerjee, S | 1 |
Kong, D | 1 |
Thakur, S | 1 |
Sarkar, FH | 2 |
Kawanami, T | 1 |
Takiguchi, S | 1 |
Ikeda, N | 1 |
Funakoshi, A | 1 |
Yuan, Y | 1 |
Qiao, M | 1 |
Zhang, Y | 1 |
Bodmer, M | 1 |
Becker, C | 1 |
Meier, C | 1 |
Jick, SS | 1 |
Meier, CR | 1 |
Bednar, F | 1 |
Simeone, DM | 1 |
Pollak, M | 1 |
Sadeghi, N | 1 |
Hassan, M | 1 |
Brower, V | 1 |
Flaherty, AM | 1 |
Kui, R | 1 |
Haq, S | 1 |
Mohammad, R | 1 |
Muniraj, T | 1 |
Chari, ST | 2 |
Singh, S | 1 |
Singh, PP | 1 |
Singh, AG | 1 |
McWilliams, RR | 1 |
Schneider, MB | 1 |
Matsuzaki, H | 1 |
Haorah, J | 1 |
Ulrich, A | 1 |
Standop, J | 1 |
Ding, XZ | 1 |
Adrian, TE | 1 |
Pour, PM | 1 |
Clinical Trials (8)
Trial Overview
Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
---|---|---|---|---|---|---|---|
Efficacy of metfOrmin in PrevenTIng Glucocorticoid-induced Diabetes in Melanoma, breAst or Lung Cancer Patients With Brain Metastases: the Phase II OPTIMAL Study[NCT04001725] | Phase 2 | 110 participants (Anticipated) | Interventional | 2019-10-15 | Recruiting | ||
An Open-Label Single-Arm Phase Ⅱ Study to Evaluate Efficacy and Safety of Sintilimab Combined With Metformin Hydrochloride in Patients With Advanced Non-small Cell Lung Cancer Refractory to First-Line Treatment[NCT03874000] | Phase 2 | 43 participants (Anticipated) | Interventional | 2019-03-08 | Recruiting | ||
The Effects of Neoadjuvant Metformin on Tumour Cell Proliferation and Tumour Progression in Pancreatic Ductal Adenocarcinoma[NCT02978547] | Phase 2 | 20 participants (Anticipated) | Interventional | 2019-01-31 | Not yet recruiting | ||
Effect of Islet Autotransplantation Compared to Oral Antidiabetic Drug in Partially Pancreatectomized Patients Due to Benign Pancreatic Neoplasm.[NCT01922492] | 28 participants (Actual) | Interventional | 2008-05-31 | Active, not recruiting | |||
A Phase II, Randomized, Placebo Controlled Study to Evaluate the Efficacy of the Combination of Gemcitabine, Erlotinib and Metformin in Patients With Locally Advanced and Metastatic Pancreatic Cancer[NCT01210911] | Phase 2 | 120 participants (Actual) | Interventional | 2010-08-31 | Completed | ||
Use of Metformin in Prevention and Treatment of Cardiac Fibrosis in PAI-1 Deficient Population[NCT05317806] | Phase 4 | 15 participants (Anticipated) | Interventional | 2022-10-10 | Active, not recruiting | ||
Metformin and Neo-adjuvant Temozolomide and Hypofractionated Accelerated Limited-margin Radiotherapy Followed by Adjuvant Temozolomide in Patients With Glioblastoma Multiforme (M-HARTT STUDY)[NCT02780024] | Phase 2 | 50 participants (Anticipated) | Interventional | 2015-03-31 | Active, not recruiting | ||
Metformin Pharmacology in Human Cancers[NCT03477162] | Early Phase 1 | 18 participants (Actual) | Interventional | 2018-05-15 | Terminated (stopped due to Enrollment was closed as efforts had become more challenging, and the lab indicated that they were able to obtain their primary objective with the number that had already been enrolled.) | ||
[information is prepared from clinicaltrials.gov, extracted Sep-2024] |
Trial Outcomes
Concentration of Metformin in Adipose Tissue
To determine the concentration of metformin in adipose tissue. (NCT03477162)
Timeframe: Within 7 days from surgery
Intervention | ng/g (Median) |
---|---|
Metformin | 70 |
Concentration of Metformin in Plasma.
To determine the concentration of metformin in plasma. (NCT03477162)
Timeframe: Within 7 days from surgery
Intervention | ng/mL (Median) |
---|---|
Metformin | 450 |
Concentration of Metformin in Tumor-adjacent Normal Tissue
To determine the concentration of metformin in tumor-adjacent normal tissue. (NCT03477162)
Timeframe: Within 7 days from surgery
Intervention | ng/g (Median) |
---|---|
Metformin | 749 |
Concentration of Metformin in Whole Blood.
To determine the concentration of metformin in whole blood. (NCT03477162)
Timeframe: Within 7 days from surgery
Intervention | ng/mL (Median) |
---|---|
Metformin | 514 |
Lung Tumor Tissue Concentration of Metformin
To determine the intra-tumor concentrations of metformin, with a standard deviation ≤25% of the mean, in patients with solid tumors of thoracic origin administered metformin extended release. (NCT03477162)
Timeframe: Within 7 days from surgery
Intervention | ng/g (Median) |
---|---|
Metformin | 1290 |
Reviews
40 reviews available for metformin and Cancer of Pancreas
Article | Year |
---|---|
Effect of metformin on
Topics: Animals; Breast Neoplasms; Carcinoma, Hepatocellular; Colonic Neoplasms; Diabetes Mellitus, Type 2; | 2022 |
Pharmacological Modulation of Apoptosis and Autophagy in Pancreatic Cancer Treatment.
Topics: Antineoplastic Agents; Apoptosis; Autophagy; Cell Line, Tumor; Cell Proliferation; Chloroquine; ErbB | 2022 |
Pharmacological Modulation of Apoptosis and Autophagy in Pancreatic Cancer Treatment.
Topics: Antineoplastic Agents; Apoptosis; Autophagy; Cell Line, Tumor; Cell Proliferation; Chloroquine; ErbB | 2022 |
Pharmacological Modulation of Apoptosis and Autophagy in Pancreatic Cancer Treatment.
Topics: Antineoplastic Agents; Apoptosis; Autophagy; Cell Line, Tumor; Cell Proliferation; Chloroquine; ErbB | 2022 |
Pharmacological Modulation of Apoptosis and Autophagy in Pancreatic Cancer Treatment.
Topics: Antineoplastic Agents; Apoptosis; Autophagy; Cell Line, Tumor; Cell Proliferation; Chloroquine; ErbB | 2022 |
The Impact of Epithelial-Mesenchymal Transition and Metformin on Pancreatic Cancer Chemoresistance: A Pathway towards Individualized Therapy.
Topics: Cell Line, Tumor; Cell Movement; Drug Resistance, Neoplasm; Epithelial-Mesenchymal Transition; Human | 2022 |
The Impact of Epithelial-Mesenchymal Transition and Metformin on Pancreatic Cancer Chemoresistance: A Pathway towards Individualized Therapy.
Topics: Cell Line, Tumor; Cell Movement; Drug Resistance, Neoplasm; Epithelial-Mesenchymal Transition; Human | 2022 |
The Impact of Epithelial-Mesenchymal Transition and Metformin on Pancreatic Cancer Chemoresistance: A Pathway towards Individualized Therapy.
Topics: Cell Line, Tumor; Cell Movement; Drug Resistance, Neoplasm; Epithelial-Mesenchymal Transition; Human | 2022 |
The Impact of Epithelial-Mesenchymal Transition and Metformin on Pancreatic Cancer Chemoresistance: A Pathway towards Individualized Therapy.
Topics: Cell Line, Tumor; Cell Movement; Drug Resistance, Neoplasm; Epithelial-Mesenchymal Transition; Human | 2022 |
Research progress on the therapeutic effect and mechanism of metformin for lung cancer (Review).
Topics: Aged; Diabetes Mellitus, Type 2; Humans; Hypoglycemic Agents; Lung Neoplasms; Metformin; Middle Aged | 2023 |
Metanalyses on metformin's role in pancreatic cancer suffer from severe bias and low data quality - An umbrella review.
Topics: Data Accuracy; Humans; Metformin; Pancreatic Neoplasms; Retrospective Studies | 2023 |
Metanalyses on metformin's role in pancreatic cancer suffer from severe bias and low data quality - An umbrella review.
Topics: Data Accuracy; Humans; Metformin; Pancreatic Neoplasms; Retrospective Studies | 2023 |
Metanalyses on metformin's role in pancreatic cancer suffer from severe bias and low data quality - An umbrella review.
Topics: Data Accuracy; Humans; Metformin; Pancreatic Neoplasms; Retrospective Studies | 2023 |
Metanalyses on metformin's role in pancreatic cancer suffer from severe bias and low data quality - An umbrella review.
Topics: Data Accuracy; Humans; Metformin; Pancreatic Neoplasms; Retrospective Studies | 2023 |
The relationship between the use of metformin and the risk of pancreatic cancer in patients with diabetes: a systematic review and meta-analysis.
Topics: Diabetes Mellitus, Type 2; Humans; Hypoglycemic Agents; Metformin; Pancreatic Neoplasms | 2023 |
The relationship between the use of metformin and the risk of pancreatic cancer in patients with diabetes: a systematic review and meta-analysis.
Topics: Diabetes Mellitus, Type 2; Humans; Hypoglycemic Agents; Metformin; Pancreatic Neoplasms | 2023 |
The relationship between the use of metformin and the risk of pancreatic cancer in patients with diabetes: a systematic review and meta-analysis.
Topics: Diabetes Mellitus, Type 2; Humans; Hypoglycemic Agents; Metformin; Pancreatic Neoplasms | 2023 |
The relationship between the use of metformin and the risk of pancreatic cancer in patients with diabetes: a systematic review and meta-analysis.
Topics: Diabetes Mellitus, Type 2; Humans; Hypoglycemic Agents; Metformin; Pancreatic Neoplasms | 2023 |
More recent, better designed studies have weakened links between antidiabetes medications and cancer risk.
Topics: Diabetes Mellitus; Dipeptidyl-Peptidase IV Inhibitors; Glucagon-Like Peptide-1 Receptor; Glycoside H | 2020 |
Relationships are between metformin use and survival in pancreatic cancer patients concurrent with diabetes: A systematic review and meta-analysis.
Topics: Aged; Clinical Trials as Topic; Diabetes Mellitus, Type 2; Female; Humans; Hypoglycemic Agents; Male | 2020 |
Metformin: review of epidemiology and mechanisms of action in pancreatic cancer.
Topics: Carcinoma, Pancreatic Ductal; Humans; Hypoglycemic Agents; Metformin; Pancreas; Pancreatic Neoplasms | 2021 |
Diabetes and pancreatic cancer: recent insights with implications for early diagnosis, treatment and prevention.
Topics: Diabetes Mellitus, Type 2; Early Detection of Cancer; Humans; Hypoglycemic Agents; Metformin; Pancre | 2021 |
Effect of Metformin and Statin Use on Survival in Pancreatic Cancer Patients: a Systematic Literature Review and Meta-analysis.
Topics: Databases, Factual; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Metformin; Odds Ratio; P | 2018 |
Metformin is associated with survival benefit in pancreatic cancer patients with diabetes: a systematic review and meta-analysis.
Topics: Diabetes Mellitus, Type 2; Humans; Hypoglycemic Agents; Metformin; Pancreatic Neoplasms; Proportiona | 2017 |
The effect of metformin on survival of patients with pancreatic cancer: a meta-analysis.
Topics: Humans; Metformin; Neoplasm Metastasis; Neoplasm Staging; Pancreatic Neoplasms; Publication Bias; Su | 2017 |
Metformin-induced anticancer activities: recent insights.
Topics: Animals; Antineoplastic Agents; Cell Proliferation; Gene Expression Regulation, Neoplastic; Humans; | 2018 |
Survival Benefits From Metformin Use in Pancreatic Cancer: A Systemic Review and Meta-analysis.
Topics: Female; Humans; Hypoglycemic Agents; Male; Metformin; Outcome Assessment, Health Care; Pancreatic Ne | 2018 |
Metformin as an Adjunctive Therapy for Pancreatic Cancer: A Review of the Literature on Its Potential Therapeutic Use.
Topics: Carcinoma, Pancreatic Ductal; Humans; Hypoglycemic Agents; Metformin; Pancreatic Neoplasms; Proof of | 2018 |
Survival Benefit of Metformin Adjuvant Treatment For Pancreatic Cancer Patients: a Systematic Review and Meta-Analysis.
Topics: Chemotherapy, Adjuvant; Databases, Factual; Disease-Free Survival; Humans; Metformin; Pancreatic Neo | 2018 |
Abilities of berberine and chemically modified berberines to interact with metformin and inhibit proliferation of pancreatic cancer cells.
Topics: AMP-Activated Protein Kinases; Berberine; Cell Proliferation; Humans; Metformin; Neoplasm Proteins; | 2019 |
Diabetes and cancer: placing the association in perspective.
Topics: Blood Glucose; Carcinoma, Pancreatic Ductal; Cell Transformation, Neoplastic; Diabetes Complications | 2013 |
Repurposing of metformin and aspirin by targeting AMPK-mTOR and inflammation for pancreatic cancer prevention and treatment.
Topics: AMP-Activated Protein Kinases; Anti-Inflammatory Agents, Non-Steroidal; Aspirin; Drug Repositioning; | 2014 |
Systematic reviews to ascertain the safety of diabetes medications.
Topics: Acidosis, Lactic; Blood Glucose; Diabetes Mellitus, Type 2; Evidence-Based Medicine; Female; Fractur | 2014 |
Metformin is associated with reduced risk of pancreatic cancer in patients with type 2 diabetes mellitus: a systematic review and meta-analysis.
Topics: Case-Control Studies; Diabetes Mellitus, Type 2; Humans; Hypoglycemic Agents; Metformin; Pancreatic | 2014 |
Diabetes mellitus as a novel risk factor for gastrointestinal malignancies.
Topics: Adenocarcinoma; Carcinoma, Hepatocellular; Colorectal Neoplasms; Diabetes Complications; Humans; Hyp | 2014 |
Metformin and pancreatic cancer: Is there a role?
Topics: Diabetes Mellitus, Type 2; Humans; Hyperinsulinism; Hypoglycemic Agents; Insulin Resistance; Metform | 2016 |
Metformin with everolimus and octreotide in pancreatic neuroendocrine tumor patients with diabetes.
Topics: Antineoplastic Agents; Comorbidity; Diabetes Mellitus; Everolimus; Humans; Hypoglycemic Agents; Metf | 2016 |
Effect of Metformin Use on Survival in Resectable Pancreatic Cancer: A Single-Institution Experience and Review of the Literature.
Topics: Adenocarcinoma; Humans; Kaplan-Meier Estimate; Metformin; Pancreatic Neoplasms | 2016 |
Metformin in pancreatic cancer treatment: from clinical trials through basic research to biomarker quantification.
Topics: Animals; Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; Humans; Metformin; Pancr | 2016 |
A Metabolic Inhibitory Cocktail for Grave Cancers: Metformin, Pioglitazone and Lithium Combination in Treatment of Pancreatic Cancer and Glioblastoma Multiforme.
Topics: Brain Neoplasms; Cell Proliferation; Drug Therapy, Combination; Gene Expression Regulation, Neoplast | 2016 |
The Role of Common Pharmaceutical Agents on the Prevention and Treatment of Pancreatic Cancer.
Topics: Adrenergic beta-Antagonists; Anticarcinogenic Agents; Antineoplastic Agents; Aspirin; Dipeptidyl-Pep | 2016 |
Aspirin in pancreatic cancer: chemopreventive effects and therapeutic potentials.
Topics: Animals; Anticarcinogenic Agents; Aspirin; Cancer Pain; Humans; Metformin; Pancreatic Neoplasms | 2016 |
Employing Metabolism to Improve the Diagnosis and Treatment of Pancreatic Cancer.
Topics: Carcinoma, Pancreatic Ductal; Cellular Reprogramming; Fluorodeoxyglucose F18; Glucose; Glutamine; Hu | 2017 |
Epidemiological aspects of neoplasms in diabetes.
Topics: Antineoplastic Agents; Breast Neoplasms; Carcinoma, Hepatocellular; Case-Control Studies; Cell Divis | 2010 |
Diabetes and pancreatic cancer: chicken or egg?
Topics: Biomarkers, Tumor; Case-Control Studies; Causality; Diabetes Complications; Diabetes Mellitus; Diabe | 2011 |
Pancreatogenic diabetes: special considerations for management.
Topics: Administration, Oral; Animals; Diabetes Mellitus; Dipeptidyl Peptidase 4; Dipeptidyl-Peptidase IV In | 2011 |
[Pancreatic diseases: update 2011].
Topics: Antineoplastic Combined Chemotherapy Protocols; Autoimmune Diseases; Diabetes Mellitus; Diagnosis, D | 2011 |
Diabetes and pancreatic cancer.
Topics: Animals; Antineoplastic Agents; Diabetes Complications; Diabetes Mellitus; Humans; Hypoglycemic Agen | 2012 |
Management of diabetes and pancreatic cancer.
Topics: Adenocarcinoma; Antiemetics; Antineoplastic Combined Chemotherapy Protocols; Combined Modality Thera | 2012 |
The complexities of epidemiology and prevention of gastrointestinal cancers.
Topics: Colorectal Neoplasms; Cyclooxygenase 2 Inhibitors; Diabetes Complications; Folic Acid; Gastrointesti | 2012 |
Diabetes and pancreatic cancer.
Topics: Age Factors; Body Mass Index; Clinical Trials as Topic; Diabetes Mellitus, Type 2; Early Detection o | 2012 |
Anti-diabetic medications and risk of pancreatic cancer in patients with diabetes mellitus: a systematic review and meta-analysis.
Topics: Diabetes Mellitus; Humans; Hypoglycemic Agents; Insulin; Metformin; Pancreatic Neoplasms; Risk Asses | 2013 |
Trials
5 trials available for metformin and Cancer of Pancreas
Article | Year |
---|---|
Study Protocol: Phase-Ib Trial of Nivolumab Combined With Metformin for Refractory/Recurrent Solid Tumors.
Topics: Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Cohort Studies; Comb | 2018 |
Tumour-educated macrophages display a mixed polarisation and enhance pancreatic cancer cell invasion.
Topics: CD11c Antigen; Cell Line, Tumor; Coculture Techniques; Diabetes Mellitus, Type 2; Female; Glucose; H | 2014 |
Improved Insulin Secretion by Autologous Islet Transplantation, Compared to Oral Antidiabetic Agents, After Distal Pancreatectomy.
Topics: Adamantane; Administration, Oral; Adult; Aged; Blood Glucose; Diabetes Mellitus, Type 2; Female; Gly | 2015 |
Metformin in patients with advanced pancreatic cancer: a double-blind, randomised, placebo-controlled phase 2 trial.
Topics: Academic Medical Centers; Adult; Aged; Analysis of Variance; Antineoplastic Combined Chemotherapy Pr | 2015 |
(Ir)relevance of Metformin Treatment in Patients with Metastatic Pancreatic Cancer: An Open-Label, Randomized Phase II Trial.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Cisplatin; Deoxycytidine; | 2016 |
Other Studies
137 other studies available for metformin and Cancer of Pancreas
Article | Year |
---|---|
Discovery and Lead Optimization of Benzene-1,4-disulfonamides as Oxidative Phosphorylation Inhibitors.
Topics: Adenosine Triphosphate; Animals; Antineoplastic Agents; Apoptosis; Cell Proliferation; Drug Discover | 2022 |
Combination therapy with interleukin-15 and metformin as a synergistic treatment for pancreatic cancer.
Topics: Animals; Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Autophagy; Cell Line; Cell Line, | 2021 |
Numb/Notch/PLK1 signaling pathway mediated hyperglycemic memory in pancreatic cancer cell radioresistance and the therapeutic effects of metformin.
Topics: Animals; Membrane Proteins; Metformin; Nerve Tissue Proteins; Pancreatic Neoplasms; Receptors, Notch | 2022 |
Numb/Notch/PLK1 signaling pathway mediated hyperglycemic memory in pancreatic cancer cell radioresistance and the therapeutic effects of metformin.
Topics: Animals; Membrane Proteins; Metformin; Nerve Tissue Proteins; Pancreatic Neoplasms; Receptors, Notch | 2022 |
Numb/Notch/PLK1 signaling pathway mediated hyperglycemic memory in pancreatic cancer cell radioresistance and the therapeutic effects of metformin.
Topics: Animals; Membrane Proteins; Metformin; Nerve Tissue Proteins; Pancreatic Neoplasms; Receptors, Notch | 2022 |
Numb/Notch/PLK1 signaling pathway mediated hyperglycemic memory in pancreatic cancer cell radioresistance and the therapeutic effects of metformin.
Topics: Animals; Membrane Proteins; Metformin; Nerve Tissue Proteins; Pancreatic Neoplasms; Receptors, Notch | 2022 |
Effectiveness and Prognostic Factors of Everolimus in Patients with Pancreatic Neuroendocrine Neoplasms.
Topics: Aged; Everolimus; Humans; Metformin; Neuroendocrine Tumors; Pancreatic Neoplasms; Prognosis | 2023 |
Risk factors for the occurrence of ampullary tumors: A case-control study.
Topics: Adenoma; Ampulla of Vater; Aspirin; Carcinoma; Case-Control Studies; Common Bile Duct Neoplasms; Duo | 2022 |
EPR Investigations to Study the Impact of Mito-Metformin on the Mitochondrial Function of Prostate Cancer Cells.
Topics: Antioxidants; Carbon; Cell Line, Tumor; Glutathione Disulfide; Humans; Male; Metformin; Mitochondria | 2022 |
Examining the relationship between metformin dose and cancer survival: A SEER-Medicare analysis.
Topics: Aged; Cohort Studies; Diabetes Mellitus, Type 2; Humans; Hypoglycemic Agents; Male; Medicare; Metfor | 2022 |
Influence of antidiabetic drugs on glucose metabolism and immune response in patients with metastatic pancreatic ductal adenocarcinoma receiving gemcitabine plus nab-paclitaxel as first-line treatment.
Topics: Adenocarcinoma; Albumins; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Pancreatic Duct | 2023 |
Influence of antidiabetic drugs on glucose metabolism and immune response in patients with metastatic pancreatic ductal adenocarcinoma receiving gemcitabine plus nab-paclitaxel as first-line treatment.
Topics: Adenocarcinoma; Albumins; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Pancreatic Duct | 2023 |
Influence of antidiabetic drugs on glucose metabolism and immune response in patients with metastatic pancreatic ductal adenocarcinoma receiving gemcitabine plus nab-paclitaxel as first-line treatment.
Topics: Adenocarcinoma; Albumins; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Pancreatic Duct | 2023 |
Influence of antidiabetic drugs on glucose metabolism and immune response in patients with metastatic pancreatic ductal adenocarcinoma receiving gemcitabine plus nab-paclitaxel as first-line treatment.
Topics: Adenocarcinoma; Albumins; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Pancreatic Duct | 2023 |
Influence of antidiabetic drugs on glucose metabolism and immune response in patients with metastatic pancreatic ductal adenocarcinoma receiving gemcitabine plus nab-paclitaxel as first-line treatment.
Topics: Adenocarcinoma; Albumins; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Pancreatic Duct | 2023 |
Influence of antidiabetic drugs on glucose metabolism and immune response in patients with metastatic pancreatic ductal adenocarcinoma receiving gemcitabine plus nab-paclitaxel as first-line treatment.
Topics: Adenocarcinoma; Albumins; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Pancreatic Duct | 2023 |
Influence of antidiabetic drugs on glucose metabolism and immune response in patients with metastatic pancreatic ductal adenocarcinoma receiving gemcitabine plus nab-paclitaxel as first-line treatment.
Topics: Adenocarcinoma; Albumins; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Pancreatic Duct | 2023 |
Influence of antidiabetic drugs on glucose metabolism and immune response in patients with metastatic pancreatic ductal adenocarcinoma receiving gemcitabine plus nab-paclitaxel as first-line treatment.
Topics: Adenocarcinoma; Albumins; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Pancreatic Duct | 2023 |
Influence of antidiabetic drugs on glucose metabolism and immune response in patients with metastatic pancreatic ductal adenocarcinoma receiving gemcitabine plus nab-paclitaxel as first-line treatment.
Topics: Adenocarcinoma; Albumins; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Pancreatic Duct | 2023 |
Influence of antidiabetic drugs on glucose metabolism and immune response in patients with metastatic pancreatic ductal adenocarcinoma receiving gemcitabine plus nab-paclitaxel as first-line treatment.
Topics: Adenocarcinoma; Albumins; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Pancreatic Duct | 2023 |
Influence of antidiabetic drugs on glucose metabolism and immune response in patients with metastatic pancreatic ductal adenocarcinoma receiving gemcitabine plus nab-paclitaxel as first-line treatment.
Topics: Adenocarcinoma; Albumins; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Pancreatic Duct | 2023 |
Influence of antidiabetic drugs on glucose metabolism and immune response in patients with metastatic pancreatic ductal adenocarcinoma receiving gemcitabine plus nab-paclitaxel as first-line treatment.
Topics: Adenocarcinoma; Albumins; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Pancreatic Duct | 2023 |
Influence of antidiabetic drugs on glucose metabolism and immune response in patients with metastatic pancreatic ductal adenocarcinoma receiving gemcitabine plus nab-paclitaxel as first-line treatment.
Topics: Adenocarcinoma; Albumins; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Pancreatic Duct | 2023 |
Influence of antidiabetic drugs on glucose metabolism and immune response in patients with metastatic pancreatic ductal adenocarcinoma receiving gemcitabine plus nab-paclitaxel as first-line treatment.
Topics: Adenocarcinoma; Albumins; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Pancreatic Duct | 2023 |
Influence of antidiabetic drugs on glucose metabolism and immune response in patients with metastatic pancreatic ductal adenocarcinoma receiving gemcitabine plus nab-paclitaxel as first-line treatment.
Topics: Adenocarcinoma; Albumins; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Pancreatic Duct | 2023 |
Influence of antidiabetic drugs on glucose metabolism and immune response in patients with metastatic pancreatic ductal adenocarcinoma receiving gemcitabine plus nab-paclitaxel as first-line treatment.
Topics: Adenocarcinoma; Albumins; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Pancreatic Duct | 2023 |
Metformin enhances the antitumor activity of oncolytic herpes simplex virus HF10 (canerpaturev) in a pancreatic cell cancer subcutaneous model.
Topics: Animals; Cell Line, Tumor; Herpesvirus 1, Human; Humans; Metformin; Mice; Oncolytic Virotherapy; Onc | 2022 |
Metformin enhances the antitumor activity of oncolytic herpes simplex virus HF10 (canerpaturev) in a pancreatic cell cancer subcutaneous model.
Topics: Animals; Cell Line, Tumor; Herpesvirus 1, Human; Humans; Metformin; Mice; Oncolytic Virotherapy; Onc | 2022 |
Metformin enhances the antitumor activity of oncolytic herpes simplex virus HF10 (canerpaturev) in a pancreatic cell cancer subcutaneous model.
Topics: Animals; Cell Line, Tumor; Herpesvirus 1, Human; Humans; Metformin; Mice; Oncolytic Virotherapy; Onc | 2022 |
Metformin enhances the antitumor activity of oncolytic herpes simplex virus HF10 (canerpaturev) in a pancreatic cell cancer subcutaneous model.
Topics: Animals; Cell Line, Tumor; Herpesvirus 1, Human; Humans; Metformin; Mice; Oncolytic Virotherapy; Onc | 2022 |
Metformin enhances the antitumor activity of oncolytic herpes simplex virus HF10 (canerpaturev) in a pancreatic cell cancer subcutaneous model.
Topics: Animals; Cell Line, Tumor; Herpesvirus 1, Human; Humans; Metformin; Mice; Oncolytic Virotherapy; Onc | 2022 |
Metformin enhances the antitumor activity of oncolytic herpes simplex virus HF10 (canerpaturev) in a pancreatic cell cancer subcutaneous model.
Topics: Animals; Cell Line, Tumor; Herpesvirus 1, Human; Humans; Metformin; Mice; Oncolytic Virotherapy; Onc | 2022 |
Metformin enhances the antitumor activity of oncolytic herpes simplex virus HF10 (canerpaturev) in a pancreatic cell cancer subcutaneous model.
Topics: Animals; Cell Line, Tumor; Herpesvirus 1, Human; Humans; Metformin; Mice; Oncolytic Virotherapy; Onc | 2022 |
Metformin enhances the antitumor activity of oncolytic herpes simplex virus HF10 (canerpaturev) in a pancreatic cell cancer subcutaneous model.
Topics: Animals; Cell Line, Tumor; Herpesvirus 1, Human; Humans; Metformin; Mice; Oncolytic Virotherapy; Onc | 2022 |
Metformin enhances the antitumor activity of oncolytic herpes simplex virus HF10 (canerpaturev) in a pancreatic cell cancer subcutaneous model.
Topics: Animals; Cell Line, Tumor; Herpesvirus 1, Human; Humans; Metformin; Mice; Oncolytic Virotherapy; Onc | 2022 |
Metformin enhances the antitumor activity of oncolytic herpes simplex virus HF10 (canerpaturev) in a pancreatic cell cancer subcutaneous model.
Topics: Animals; Cell Line, Tumor; Herpesvirus 1, Human; Humans; Metformin; Mice; Oncolytic Virotherapy; Onc | 2022 |
Metformin enhances the antitumor activity of oncolytic herpes simplex virus HF10 (canerpaturev) in a pancreatic cell cancer subcutaneous model.
Topics: Animals; Cell Line, Tumor; Herpesvirus 1, Human; Humans; Metformin; Mice; Oncolytic Virotherapy; Onc | 2022 |
Metformin enhances the antitumor activity of oncolytic herpes simplex virus HF10 (canerpaturev) in a pancreatic cell cancer subcutaneous model.
Topics: Animals; Cell Line, Tumor; Herpesvirus 1, Human; Humans; Metformin; Mice; Oncolytic Virotherapy; Onc | 2022 |
Metformin enhances the antitumor activity of oncolytic herpes simplex virus HF10 (canerpaturev) in a pancreatic cell cancer subcutaneous model.
Topics: Animals; Cell Line, Tumor; Herpesvirus 1, Human; Humans; Metformin; Mice; Oncolytic Virotherapy; Onc | 2022 |
Metformin enhances the antitumor activity of oncolytic herpes simplex virus HF10 (canerpaturev) in a pancreatic cell cancer subcutaneous model.
Topics: Animals; Cell Line, Tumor; Herpesvirus 1, Human; Humans; Metformin; Mice; Oncolytic Virotherapy; Onc | 2022 |
Metformin enhances the antitumor activity of oncolytic herpes simplex virus HF10 (canerpaturev) in a pancreatic cell cancer subcutaneous model.
Topics: Animals; Cell Line, Tumor; Herpesvirus 1, Human; Humans; Metformin; Mice; Oncolytic Virotherapy; Onc | 2022 |
Metformin enhances the antitumor activity of oncolytic herpes simplex virus HF10 (canerpaturev) in a pancreatic cell cancer subcutaneous model.
Topics: Animals; Cell Line, Tumor; Herpesvirus 1, Human; Humans; Metformin; Mice; Oncolytic Virotherapy; Onc | 2022 |
Metformin inhibits neutrophil extracellular traps-promoted pancreatic carcinogenesis in obese mice.
Topics: Animals; Carcinogenesis; Carcinoma in Situ; Carcinoma, Pancreatic Ductal; Extracellular Traps; Metfo | 2023 |
Reverse causation biases weighted cumulative exposure model estimates, but can be investigated in sensitivity analyses.
Topics: Bias; Causality; Diabetes Mellitus; Humans; Metformin; Pancreatic Neoplasms; Risk Factors | 2023 |
Glucose-responsive Insulinoma with Insulin Hypersecretion Suppressed by Metformin.
Topics: Glucose Tolerance Test; Humans; Hypoglycemia; Hypoglycemic Agents; Insulin; Insulinoma; Male; Metfor | 2019 |
Metformin Use and Pancreatic Cancer Survival among Non-Hispanic White and African American U.S. Veterans with Diabetes Mellitus.
Topics: Aged; Black or African American; Carcinoma, Pancreatic Ductal; Chemotherapy, Adjuvant; Comorbidity; | 2020 |
The Postoperative Occurrence or Worsening of Diabetes Mellitus May Increase the Risk of Recurrence in Resected Pancreatic Neuroendocrine Tumors.
Topics: Adult; Aged; Diabetes Mellitus; Female; Follow-Up Studies; Humans; Hypoglycemic Agents; Male; Metfor | 2020 |
Metformin turns off the metabolic switch of pancreatic cancer.
Topics: Cell Proliferation; Cellular Senescence; Gene Expression Regulation; Humans; Hypoglycemic Agents; Me | 2019 |
Mechanism of metformin enhancing the sensitivity of human pancreatic cancer cells to gem-citabine by regulating the PI3K/Akt/mTOR signaling pathway.
Topics: Cell Line, Tumor; Cell Proliferation; Deoxycytidine; Drug Resistance, Neoplasm; Gemcitabine; Gene Ex | 2019 |
Metformin Inhibits Proliferation and Tumor Growth of QGP-1 Pancreatic Neuroendocrine Tumor Cells by Inducing Cell Cycle Arrest and Apoptosis.
Topics: Apoptosis; Biomarkers; Carcinoma, Neuroendocrine; Cell Cycle Checkpoints; Cell Line, Tumor; Cell Pro | 2020 |
Galloflavin Plus Metformin Treatment Impairs Pancreatic Cancer Cells.
Topics: Antineoplastic Agents; Biomarkers; Cell Line, Tumor; Cell Proliferation; Dose-Response Relationship, | 2020 |
Metformin-Induced Stromal Depletion to Enhance the Penetration of Gemcitabine-Loaded Magnetic Nanoparticles for Pancreatic Cancer Targeted Therapy.
Topics: Adenocarcinoma; Amino Acid Sequence; Animals; Antineoplastic Agents; Carcinoma, Pancreatic Ductal; C | 2020 |
An observational study to justify and plan a future phase III randomized controlled trial of metformin in improving overall survival in patients with inoperable pancreatic cancer without liver metastases.
Topics: Aged; Carcinoma, Pancreatic Ductal; Clinical Trials, Phase III as Topic; Cross-Sectional Studies; Fe | 2020 |
A novel insight into the anticancer mechanism of metformin in pancreatic neuroendocrine tumor cells.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Apoptosis; Cell Cycle Proteins; Cell Line, Tu | 2020 |
Oncological benefit of metformin in patients with pancreatic ductal adenocarcinoma and comorbid diabetes mellitus.
Topics: Adult; Aged; Carcinoma, Pancreatic Ductal; Diabetes Complications; Female; Humans; Hypoglycemic Agen | 2020 |
ISG15 and ISGylation is required for pancreatic cancer stem cell mitophagy and metabolic plasticity.
Topics: Carcinoma, Pancreatic Ductal; Cell Line; Cell Plasticity; Cell Transformation, Neoplastic; Cytokines | 2020 |
Metformin reduces pancreatic cancer cell proliferation and increases apoptosis through MTOR signaling pathway and its dose-effect relationship.
Topics: Antineoplastic Agents; Apoptosis; Cell Proliferation; Dose-Response Relationship, Drug; Drug Screeni | 2020 |
Diabetes Is Associated With the Metastasis of Pancreatic Neuroendocrine Tumors.
Topics: China; Diabetes Mellitus, Type 2; Female; Humans; Hypoglycemic Agents; Kaplan-Meier Estimate; Male; | 2020 |
Metformin inhibits TGF‑β1‑induced epithelial‑mesenchymal transition and liver metastasis of pancreatic cancer cells.
Topics: Animals; Antigens, CD; Cadherins; Cell Line, Tumor; Cell Proliferation; Cell Survival; Epithelial-Me | 2020 |
Low glucose enhanced metformin's inhibitory effect on pancreatic cancer cells by suppressing glycolysis and inducing energy stress via up-regulation of miR-210-5p.
Topics: Anaerobiosis; Apoptosis; Cell Line, Tumor; Cell Proliferation; Cell Survival; Down-Regulation; Energ | 2020 |
Metformin inhibits pancreatic cancer metastasis caused by SMAD4 deficiency and consequent HNF4G upregulation.
Topics: Animals; Cell Line; Female; Gene Expression Regulation, Neoplastic; Hepatocyte Nuclear Factor 4; Hum | 2021 |
Repurposing metformin, simvastatin and digoxin as a combination for targeted therapy for pancreatic ductal adenocarcinoma.
Topics: Animals; Carcinoma, Pancreatic Ductal; Cell Line, Tumor; Digoxin; Drug Combinations; Drug Reposition | 2020 |
Hyaluronic Acid Conjugated Metformin-Phospholipid Sonocomplex: A Biphasic Complexation Approach to Correct Hypoxic Tumour Microenvironment.
Topics: 1-Octanol; Animals; Cell Line, Tumor; Cell Proliferation; Glucose; Humans; Hyaluronic Acid; Hypoxia- | 2021 |
TET2 Drives 5hmc Marking of GATA6 and Epigenetically Defines Pancreatic Ductal Adenocarcinoma Transcriptional Subtypes.
Topics: 5-Methylcytosine; Animals; Antineoplastic Combined Chemotherapy Protocols; Ascorbic Acid; Biomarkers | 2021 |
GSK-3β Can Regulate the Sensitivity of MIA-PaCa-2 Pancreatic and MCF-7 Breast Cancer Cells to Chemotherapeutic Drugs, Targeted Therapeutics and Nutraceuticals.
Topics: Adenocarcinoma; Adenylate Kinase; Antineoplastic Agents; bcl-X Protein; Berberine; Biphenyl Compound | 2021 |
Use of non-cancer drugs and survival among patients with pancreatic adenocarcinoma: a nationwide registry-based study in Norway.
Topics: Adenocarcinoma; Cohort Studies; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Metformin; P | 2021 |
Modified Metformin as a More Potent Anticancer Drug: Mitochondrial Inhibition, Redox Signaling, Antiproliferative Effects and Future EPR Studies.
Topics: Antineoplastic Agents; Cell Line, Tumor; Cell Proliferation; Electron Spin Resonance Spectroscopy; E | 2017 |
Differential and Joint Effects of Metformin and Statins on Overall Survival of Elderly Patients with Pancreatic Adenocarcinoma: A Large Population-Based Study.
Topics: Adenocarcinoma; Aged; Cohort Studies; Female; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors | 2017 |
Differential and Joint Effects of Metformin and Statins on Overall Survival of Elderly Patients with Pancreatic Adenocarcinoma: A Large Population-Based Study.
Topics: Adenocarcinoma; Aged; Cohort Studies; Female; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors | 2017 |
Differential and Joint Effects of Metformin and Statins on Overall Survival of Elderly Patients with Pancreatic Adenocarcinoma: A Large Population-Based Study.
Topics: Adenocarcinoma; Aged; Cohort Studies; Female; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors | 2017 |
Differential and Joint Effects of Metformin and Statins on Overall Survival of Elderly Patients with Pancreatic Adenocarcinoma: A Large Population-Based Study.
Topics: Adenocarcinoma; Aged; Cohort Studies; Female; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors | 2017 |
Metformin suppresses cancer initiation and progression in genetic mouse models of pancreatic cancer.
Topics: Animals; Carcinogenesis; Carcinoma in Situ; Carcinoma, Pancreatic Ductal; Disease Models, Animal; Di | 2017 |
Crucial microRNAs and genes in metformin's anti-pancreatic cancer effect explored by microRNA-mRNA integrated analysis.
Topics: Antineoplastic Agents; Cell Line, Tumor; Gene Expression Regulation, Neoplastic; Humans; Hypoglycemi | 2018 |
Preliminary Results that Assess Metformin Treatment in a Preclinical Model of Pancreatic Cancer Using Simultaneous [
Topics: Animals; Biomarkers, Tumor; Cell Line, Tumor; Female; Fluorodeoxyglucose F18; Humans; Magnetic Reson | 2018 |
Oncogenic HSP60 regulates mitochondrial oxidative phosphorylation to support Erk1/2 activation during pancreatic cancer cell growth.
Topics: Adenocarcinoma; Adenosine Triphosphate; Animals; Apoptosis; Carcinogenesis; Carcinoma, Pancreatic Du | 2018 |
Metformin influences drug sensitivity in pancreatic cancer cells.
Topics: Animals; Carcinoma, Pancreatic Ductal; Diabetes Mellitus, Type 2; Drug Interactions; Humans; Metform | 2018 |
Metformin influences drug sensitivity in pancreatic cancer cells.
Topics: Animals; Carcinoma, Pancreatic Ductal; Diabetes Mellitus, Type 2; Drug Interactions; Humans; Metform | 2018 |
Metformin influences drug sensitivity in pancreatic cancer cells.
Topics: Animals; Carcinoma, Pancreatic Ductal; Diabetes Mellitus, Type 2; Drug Interactions; Humans; Metform | 2018 |
Metformin influences drug sensitivity in pancreatic cancer cells.
Topics: Animals; Carcinoma, Pancreatic Ductal; Diabetes Mellitus, Type 2; Drug Interactions; Humans; Metform | 2018 |
LKB1 obliterates Snail stability and inhibits pancreatic cancer metastasis in response to metformin treatment.
Topics: AMP-Activated Protein Kinase Kinases; Animals; Carcinoma, Pancreatic Ductal; Cell Line, Tumor; Cell | 2018 |
α-cyano-4-hydroxycinnamate impairs pancreatic cancer cells by stimulating the p38 signaling pathway.
Topics: Animals; Apoptosis; Cell Line, Tumor; Cell Movement; Cell Proliferation; Coumaric Acids; Hexokinase; | 2018 |
Metformin Decreases the Incidence of Pancreatic Ductal Adenocarcinoma Promoted by Diet-induced Obesity in the Conditional KrasG12D Mouse Model.
Topics: Acyltransferases; Administration, Oral; Animals; Carcinogenesis; Carcinoma, Pancreatic Ductal; Chemo | 2018 |
Metformin Use Is Associated With Longer Progression-Free Survival of Patients With Diabetes and Pancreatic Neuroendocrine Tumors Receiving Everolimus and/or Somatostatin Analogues.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Child; Diabetes Mellitus, Type 2; | 2018 |
Synergistic anti-tumor effects of liraglutide with metformin on pancreatic cancer cells.
Topics: AMP-Activated Protein Kinases; bcl-2-Associated X Protein; Caspase 3; Cell Cycle Checkpoints; Cell L | 2018 |
The influence of diabetes and antidiabetic medications on the risk of pancreatic cancer: a nationwide population-based study in Korea.
Topics: Adult; Aged; Diabetes Mellitus, Type 2; Dipeptidyl-Peptidase IV Inhibitors; Female; Humans; Hypoglyc | 2018 |
Metformin suppresses the invasive ability of pancreatic cancer cells by blocking autocrine TGF‑β1 signaling.
Topics: Animals; Apoptosis; Autocrine Communication; Biomarkers, Tumor; Carcinoma, Pancreatic Ductal; Cell M | 2018 |
Metformin suppresses tumor angiogenesis and enhances the chemosensitivity of gemcitabine in a genetically engineered mouse model of pancreatic cancer.
Topics: Animals; Antimetabolites, Antineoplastic; Carcinoma, Pancreatic Ductal; Cell Proliferation; Deoxycyt | 2018 |
Metformin and Pancreatic Cancer Risk in Patients With Type 2 Diabetes.
Topics: Diabetes Mellitus, Type 2; Humans; Hypoglycemic Agents; Incidence; Metformin; Pancreatic Neoplasms; | 2018 |
Glycemic Variability Promotes Both Local Invasion and Metastatic Colonization by Pancreatic Ductal Adenocarcinoma.
Topics: Animals; Carcinoma, Pancreatic Ductal; Cell Line, Tumor; Cell Proliferation; Collagen Type VI; Core | 2018 |
Glycemic Variability Promotes Both Local Invasion and Metastatic Colonization by Pancreatic Ductal Adenocarcinoma.
Topics: Animals; Carcinoma, Pancreatic Ductal; Cell Line, Tumor; Cell Proliferation; Collagen Type VI; Core | 2018 |
Glycemic Variability Promotes Both Local Invasion and Metastatic Colonization by Pancreatic Ductal Adenocarcinoma.
Topics: Animals; Carcinoma, Pancreatic Ductal; Cell Line, Tumor; Cell Proliferation; Collagen Type VI; Core | 2018 |
Glycemic Variability Promotes Both Local Invasion and Metastatic Colonization by Pancreatic Ductal Adenocarcinoma.
Topics: Animals; Carcinoma, Pancreatic Ductal; Cell Line, Tumor; Cell Proliferation; Collagen Type VI; Core | 2018 |
Treatment with incretins does not increase the risk of pancreatic diseases compared to older anti-hyperglycaemic drugs, when added to metformin: real world evidence in people with Type 2 diabetes.
Topics: Acute Disease; Aged; Diabetes Mellitus, Type 2; Dipeptidyl-Peptidase IV Inhibitors; Drug Therapy, Co | 2019 |
Mechanisms of metformin's anti‑tumor activity against gemcitabine‑resistant pancreatic adenocarcinoma.
Topics: Animals; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Pancreatic Ductal; Deoxycytidine | 2019 |
Metformin and pancreatic cancer survival: Real effect or immortal time bias?
Topics: Bias; Databases, Bibliographic; Evidence-Based Medicine; Female; Humans; Male; Metformin; Pancreatic | 2019 |
Association between pancreatic cancer and metformin use in patients with type 2 diabetes.
Topics: Case-Control Studies; Diabetes Mellitus, Type 2; Humans; Hypoglycemic Agents; Logistic Models; Metfo | 2019 |
Antidiabetic Medications and Mortality Risk in Individuals With Pancreatic Cancer-Related Diabetes and Postpancreatitis Diabetes: A Nationwide Cohort Study.
Topics: Adult; Aged; Aged, 80 and over; Cohort Studies; Diabetes Mellitus, Type 2; Female; Humans; Hypoglyce | 2019 |
Metformin Associated With Increased Survival in Type 2 Diabetes Patients With Pancreatic Cancer and Lymphoma.
Topics: Aged; Diabetes Mellitus, Type 2; Female; Humans; Hypoglycemic Agents; Lymphoma; Male; Metformin; Mid | 2019 |
Different patterns of Akt and ERK feedback activation in response to rapamycin, active-site mTOR inhibitors and metformin in pancreatic cancer cells.
Topics: Antibiotics, Antineoplastic; Carcinoma, Pancreatic Ductal; Cell Line, Tumor; Cell Proliferation; Ext | 2013 |
Metformin inhibits the growth of human pancreatic cancer xenografts.
Topics: Administration, Oral; Animals; Blotting, Western; Body Weight; Cell Line, Tumor; Dose-Response Relat | 2013 |
Metformin-mediated growth inhibition involves suppression of the IGF-I receptor signalling pathway in human pancreatic cancer cells.
Topics: AMP-Activated Protein Kinases; Analysis of Variance; Apoptosis; Cell Line, Tumor; Cell Proliferation | 2013 |
Low concentrations of metformin selectively inhibit CD133⁺ cell proliferation in pancreatic cancer and have anticancer action.
Topics: AC133 Antigen; Antigens, CD; Blotting, Western; Cell Line, Tumor; Cell Proliferation; Dose-Response | 2013 |
One year of sitagliptin treatment protects against islet amyloid-associated β-cell loss and does not induce pancreatitis or pancreatic neoplasia in mice.
Topics: Animals; Diabetes Mellitus, Type 2; Dipeptidyl-Peptidase IV Inhibitors; Drug Therapy, Combination; H | 2013 |
Metformin inhibits pancreatic cancer cell and tumor growth and downregulates Sp transcription factors.
Topics: Antineoplastic Agents; Cell Line, Tumor; Cell Proliferation; Down-Regulation; Gene Expression Regula | 2013 |
Diabetes and pancreatic cancer.
Topics: Adenocarcinoma; Diabetes Mellitus; Glycated Hemoglobin; Humans; Hypoglycemic Agents; Metformin; Panc | 2013 |
Metformin and survival in pancreatic cancer: a retrospective cohort study.
Topics: Aged; Aged, 80 and over; Cohort Studies; Diabetes Mellitus, Type 2; Female; Humans; Hypoglycemic Age | 2013 |
A prospective, claims-based assessment of the risk of pancreatitis and pancreatic cancer with liraglutide compared to other antidiabetic drugs.
Topics: Databases, Factual; Dipeptidyl-Peptidase IV Inhibitors; Female; Glucagon-Like Peptide 1; Humans; Hyp | 2014 |
Metformin targets the metabolic achilles heel of human pancreatic cancer stem cells.
Topics: Biomarkers; Carcinoma, Pancreatic Ductal; Cell Line, Tumor; Cell Transformation, Neoplastic; Disease | 2013 |
Diabetes and pancreatic cancer.
Topics: Diabetes Complications; Early Diagnosis; Humans; Metformin; Pancreatic Neoplasms; Risk Factors; Surv | 2014 |
Metformin suppresses sonic hedgehog expression in pancreatic cancer cells.
Topics: Antineoplastic Agents; Cell Line, Tumor; Drug Resistance, Neoplasm; Gene Expression Regulation, Neop | 2014 |
O-carboxymethyl chitosan nanoparticles for metformin delivery to pancreatic cancer cells.
Topics: Cell Line, Tumor; Chitosan; Drug Carriers; Hemolysis; Humans; Metformin; Microscopy, Electron, Scann | 2012 |
Profiling and targeting of cellular bioenergetics: inhibition of pancreatic cancer cell proliferation.
Topics: Adenosine Triphosphate; Antineoplastic Agents; Celecoxib; Cell Culture Techniques; Cell Growth Proce | 2014 |
Profiling and targeting of cellular bioenergetics: inhibition of pancreatic cancer cell proliferation.
Topics: Adenosine Triphosphate; Antineoplastic Agents; Celecoxib; Cell Culture Techniques; Cell Growth Proce | 2014 |
Profiling and targeting of cellular bioenergetics: inhibition of pancreatic cancer cell proliferation.
Topics: Adenosine Triphosphate; Antineoplastic Agents; Celecoxib; Cell Culture Techniques; Cell Growth Proce | 2014 |
Profiling and targeting of cellular bioenergetics: inhibition of pancreatic cancer cell proliferation.
Topics: Adenosine Triphosphate; Antineoplastic Agents; Celecoxib; Cell Culture Techniques; Cell Growth Proce | 2014 |
Metformin attenuates palmitate-induced endoplasmic reticulum stress, serine phosphorylation of IRS-1 and apoptosis in rat insulinoma cells.
Topics: Animals; Apoptosis; Caspase 3; Cell Line, Tumor; Endoplasmic Reticulum Stress; Eukaryotic Initiation | 2014 |
Radiosensitization of pancreatic cancer cells by metformin through the AMPK pathway.
Topics: AMP-Activated Protein Kinases; Cell Cycle; Cell Line, Tumor; Cell Survival; DNA Damage; DNA Repair; | 2014 |
Chemotherapy and metformin in pancreatic adenocarcinoma and neuroendocrine tumors.
Topics: Adenocarcinoma; AMP-Activated Protein Kinases; Antineoplastic Combined Chemotherapy Protocols; Human | 2014 |
Second-line treatment for pancreatic cancer.
Topics: Albumins; Antineoplastic Combined Chemotherapy Protocols; Deoxycytidine; Docetaxel; Drug Resistance, | 2014 |
Metformin use among type 2 diabetics and risk of pancreatic cancer in a clinic-based case-control study.
Topics: Adult; Aged; Case-Control Studies; Diabetes Mellitus, Type 2; Female; Humans; Hypoglycemic Agents; L | 2015 |
In vitro and in vivo biological evaluation of O-carboxymethyl chitosan encapsulated metformin nanoparticles for pancreatic cancer therapy.
Topics: Animals; Antineoplastic Agents; Cell Cycle; Cell Line, Tumor; Cell Movement; Chitosan; Colony-Formin | 2014 |
Nicotine promotes initiation and progression of KRAS-induced pancreatic cancer via Gata6-dependent dedifferentiation of acinar cells in mice.
Topics: Acinar Cells; alpha7 Nicotinic Acetylcholine Receptor; Animals; Carcinoma, Pancreatic Ductal; Cell D | 2014 |
Mechanism of metformin-dependent inhibition of mammalian target of rapamycin (mTOR) and Ras activity in pancreatic cancer: role of specificity protein (Sp) transcription factors.
Topics: Animals; Antineoplastic Agents; Cell Line, Tumor; Down-Regulation; Gene Expression Regulation, Neopl | 2014 |
Mechanism of metformin-dependent inhibition of mammalian target of rapamycin (mTOR) and Ras activity in pancreatic cancer: role of specificity protein (Sp) transcription factors.
Topics: Animals; Antineoplastic Agents; Cell Line, Tumor; Down-Regulation; Gene Expression Regulation, Neopl | 2014 |
Mechanism of metformin-dependent inhibition of mammalian target of rapamycin (mTOR) and Ras activity in pancreatic cancer: role of specificity protein (Sp) transcription factors.
Topics: Animals; Antineoplastic Agents; Cell Line, Tumor; Down-Regulation; Gene Expression Regulation, Neopl | 2014 |
Mechanism of metformin-dependent inhibition of mammalian target of rapamycin (mTOR) and Ras activity in pancreatic cancer: role of specificity protein (Sp) transcription factors.
Topics: Animals; Antineoplastic Agents; Cell Line, Tumor; Down-Regulation; Gene Expression Regulation, Neopl | 2014 |
Dose-Dependent AMPK-Dependent and Independent Mechanisms of Berberine and Metformin Inhibition of mTORC1, ERK, DNA Synthesis and Proliferation in Pancreatic Cancer Cells.
Topics: Acetyl-CoA Carboxylase; Adenocarcinoma; AMP-Activated Protein Kinases; Animals; Berberine; Carcinoma | 2014 |
Metformin and Rapamycin Reduce Pancreatic Cancer Growth in Obese Prediabetic Mice by Distinct MicroRNA-Regulated Mechanisms.
Topics: Animals; Body Weight; Cell Cycle; Diet, Diabetic; Energy Intake; Glucose Intolerance; Hypoglycemic A | 2015 |
The Impact of Diabetes Mellitus and Metformin Treatment on Survival of Patients with Advanced Pancreatic Cancer Undergoing Chemotherapy.
Topics: Diabetes Complications; Diabetes Mellitus; Humans; Hypoglycemic Agents; Metformin; Pancreatic Neopla | 2016 |
Resistance to gemcitabine in the pancreatic cancer cell line KLM1-R reversed by metformin action.
Topics: Cell Line, Tumor; Cell Proliferation; Deoxycytidine; Drug Resistance, Neoplasm; Gemcitabine; Heat-Sh | 2015 |
Metformin suppresses pancreatic tumor growth with inhibition of NFκB/STAT3 inflammatory signaling.
Topics: Animals; Antineoplastic Agents; Biomarkers, Tumor; Blotting, Western; Drug Administration Schedule; | 2015 |
Impact of diabetes type II and chronic inflammation on pancreatic cancer.
Topics: Aldehyde Dehydrogenase; Aldehyde Dehydrogenase 1 Family; Animals; Cell Death; Cell Line, Tumor; Cell | 2015 |
Metformin Causes G1-Phase Arrest via Down-Regulation of MiR-221 and Enhances TRAIL Sensitivity through DR5 Up-Regulation in Pancreatic Cancer Cells.
Topics: Antineoplastic Agents; Apoptosis; Apoptosis Regulatory Proteins; Bcl-2-Like Protein 11; Cell Line, T | 2015 |
Association between Gastroenterological Malignancy and Diabetes Mellitus and Anti-Diabetic Therapy: A Nationwide, Population-Based Cohort Study.
Topics: Adult; Cohort Studies; Colorectal Neoplasms; Diabetes Mellitus; Female; Glycoside Hydrolase Inhibito | 2015 |
Metformin may improve the prognosis of patients with pancreatic cancer.
Topics: Diabetes Complications; Diabetes Mellitus, Type 2; Humans; Hypoglycemic Agents; Meta-Analysis as Top | 2015 |
Metformin combined with aspirin significantly inhibit pancreatic cancer cell growth in vitro and in vivo by suppressing anti-apoptotic proteins Mcl-1 and Bcl-2.
Topics: Animals; Antineoplastic Agents; Apoptosis; Apoptosis Regulatory Proteins; Aspirin; Bcl-2-Like Protei | 2015 |
Metformin for pancreatic cancer.
Topics: Antineoplastic Combined Chemotherapy Protocols; Female; Humans; Male; Metformin; Pancreatic Neoplasm | 2015 |
Studying Pancreatic Cancer Stem Cell Characteristics for Developing New Treatment Strategies.
Topics: Animals; Carcinoma, Pancreatic Ductal; Cell Culture Techniques; Female; Humans; Metformin; Mice; Mic | 2015 |
Transcriptomic analysis of pancreatic cancer cells in response to metformin and aspirin: an implication of synergy.
Topics: Aspirin; Cell Line, Tumor; Down-Regulation; Drug Synergism; Gene Expression Profiling; Gene Expressi | 2015 |
Combination of Anti-Diabetic Drug Metformin and Boswellic Acid Nanoparticles: A Novel Strategy for Pancreatic Cancer Therapy.
Topics: Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Diffusion; Dose-Response Relationship, Dr | 2015 |
Radiosensitization of metformin in pancreatic cancer cells via abrogating the G2 checkpoint and inhibiting DNA damage repair.
Topics: Apoptosis; CDC2 Protein Kinase; Cell Cycle Proteins; Cell Line, Tumor; Chemoradiotherapy; Cyclin-Dep | 2015 |
MYC/PGC-1α Balance Determines the Metabolic Phenotype and Plasticity of Pancreatic Cancer Stem Cells.
Topics: AC133 Antigen; Animals; Antigens, CD; Antineoplastic Agents; Drug Resistance, Neoplasm; Gene Library | 2015 |
Metformin Increases Sensitivity of Pancreatic Cancer Cells to Gemcitabine by Reducing CD133+ Cell Populations and Suppressing ERK/P70S6K Signaling.
Topics: AC133 Antigen; Animals; Antigens, CD; Cell Line, Tumor; Deoxycytidine; Disease Models, Animal; Drug | 2015 |
Increased Serum Insulin Exposure Does Not Affect Age or Stage of Pancreatic Adenocarcinoma Diagnosis in Patients With Diabetes Mellitus.
Topics: Adenocarcinoma; Age of Onset; Aged; Alcohol Drinking; Body Mass Index; Cohort Studies; Diabetes Mell | 2016 |
Statin and Metformin Use Prolongs Survival in Patients With Resectable Pancreatic Cancer.
Topics: Adult; Aged; Aged, 80 and over; California; Carcinoma, Pancreatic Ductal; Disease-Free Survival; Fem | 2016 |
New-onset type 2 diabetes, elevated HbA1c, anti-diabetic medications, and risk of pancreatic cancer.
Topics: Aged; Case-Control Studies; Diabetes Mellitus, Type 2; Female; Glycated Hemoglobin; Humans; Hypoglyc | 2015 |
Impact of Metformin on Advanced Pancreatic Cancer Survival: Too Little, Too Late?
Topics: Humans; Metformin; Pancreatic Neoplasms | 2016 |
Metformin Reduces Desmoplasia in Pancreatic Cancer by Reprogramming Stellate Cells and Tumor-Associated Macrophages.
Topics: Adenocarcinoma; Animals; Carcinoma, Pancreatic Ductal; Cell Movement; Cell Proliferation; Epithelial | 2015 |
Metformin Restrains Pancreatic Duodenal Homeobox-1 (PDX-1) Function by Inhibiting ERK Signaling in Pancreatic Ductal Adenocarcinoma.
Topics: Adenocarcinoma; Carcinoma, Pancreatic Ductal; Cell Line; Cell Line, Tumor; Diabetes Mellitus, Type 2 | 2016 |
Metformin Restrains Pancreatic Duodenal Homeobox-1 (PDX-1) Function by Inhibiting ERK Signaling in Pancreatic Ductal Adenocarcinoma.
Topics: Adenocarcinoma; Carcinoma, Pancreatic Ductal; Cell Line; Cell Line, Tumor; Diabetes Mellitus, Type 2 | 2016 |
Metformin Restrains Pancreatic Duodenal Homeobox-1 (PDX-1) Function by Inhibiting ERK Signaling in Pancreatic Ductal Adenocarcinoma.
Topics: Adenocarcinoma; Carcinoma, Pancreatic Ductal; Cell Line; Cell Line, Tumor; Diabetes Mellitus, Type 2 | 2016 |
Metformin Restrains Pancreatic Duodenal Homeobox-1 (PDX-1) Function by Inhibiting ERK Signaling in Pancreatic Ductal Adenocarcinoma.
Topics: Adenocarcinoma; Carcinoma, Pancreatic Ductal; Cell Line; Cell Line, Tumor; Diabetes Mellitus, Type 2 | 2016 |
The anti-diabetic drug metformin inhibits pancreatic cancer cell proliferation in vitro and in vivo: Study of the microRNAs associated with the antitumor effect of metformin.
Topics: Animals; Cell Line, Tumor; Cell Proliferation; Cyclin D1; ErbB Receptors; Gene Expression Regulation | 2016 |
Bulk pancreatic cancer cells can convert into cancer stem cells(CSCs) in vitro and 2 compounds can target these CSCs.
Topics: Animals; ATP Binding Cassette Transporter, Subfamily G, Member 2; beta Catenin; Cell Line, Tumor; Ce | 2016 |
Metformin Treatment Does Not Inhibit Growth of Pancreatic Cancer Patient-Derived Xenografts.
Topics: AMP-Activated Protein Kinases; Animals; Cell Line, Tumor; Cell Proliferation; Disease Models, Animal | 2016 |
Can metformin change the prognosis of pancreatic cancer? Retrospective study for pancreatic cancer patients with pre-existing diabetes mellitus type 2.
Topics: Adult; Aged; Aged, 80 and over; CA-19-9 Antigen; Diabetes Mellitus, Type 2; Female; Humans; Hypoglyc | 2016 |
PlGF/VEGFR-1 Signaling Promotes Macrophage Polarization and Accelerated Tumor Progression in Obesity.
Topics: Animals; Breast Neoplasms; Diet, High-Fat; Female; Glucose; Humans; Hypoglycemic Agents; Macrophages | 2016 |
Metformin Use and Survival of Patients With Pancreatic Cancer: A Cautionary Lesson.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Carcinoma, Pancreatic Ductal; Female; Humans; Male; | 2016 |
[The risk is higher, but why?].
Topics: Carcinoma, Hepatocellular; Diabetes Complications; Humans; Liver Neoplasms; Metformin; Neoplasms; Pa | 2016 |
Mitochondria-Targeted Analogues of Metformin Exhibit Enhanced Antiproliferative and Radiosensitizing Effects in Pancreatic Cancer Cells.
Topics: Animals; Apoptosis; Blotting, Western; Carcinoma, Pancreatic Ductal; Cell Cycle; Cell Proliferation; | 2016 |
Metformin Use Is Associated with Improved Survival in Patients Undergoing Resection for Pancreatic Cancer.
Topics: Diabetes Mellitus; Female; Humans; Hypoglycemic Agents; Lymphatic Metastasis; Male; Metformin; Middl | 2016 |
Metformin Improves Survival in Patients with Pancreatic Ductal Adenocarcinoma and Pre-Existing Diabetes: A Propensity Score Analysis.
Topics: Aged; Aged, 80 and over; Carcinoma, Pancreatic Ductal; Comorbidity; Diabetes Mellitus, Type 2; Femal | 2016 |
Intratumoral heterogeneity of the therapeutical response to gemcitabine and metformin.
Topics: Adenocarcinoma; Animals; Antineoplastic Combined Chemotherapy Protocols; Blood Glucose; Cell Hypoxia | 2016 |
Intratumoral heterogeneity of the therapeutical response to gemcitabine and metformin.
Topics: Adenocarcinoma; Animals; Antineoplastic Combined Chemotherapy Protocols; Blood Glucose; Cell Hypoxia | 2016 |
Intratumoral heterogeneity of the therapeutical response to gemcitabine and metformin.
Topics: Adenocarcinoma; Animals; Antineoplastic Combined Chemotherapy Protocols; Blood Glucose; Cell Hypoxia | 2016 |
Intratumoral heterogeneity of the therapeutical response to gemcitabine and metformin.
Topics: Adenocarcinoma; Animals; Antineoplastic Combined Chemotherapy Protocols; Blood Glucose; Cell Hypoxia | 2016 |
Inhibitory effect of metformin combined with gemcitabine on pancreatic cancer cells in vitro and in vivo.
Topics: Animals; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Apoptosis; | 2016 |
Combination therapy with BPTES nanoparticles and metformin targets the metabolic heterogeneity of pancreatic cancer.
Topics: Animals; Antineoplastic Combined Chemotherapy Protocols; Benzeneacetamides; Cell Line, Tumor; Glutam | 2016 |
Metformin potentiates anti-tumor effect of resveratrol on pancreatic cancer by down-regulation of VEGF-B signaling pathway.
Topics: Animals; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Apoptosi | 2016 |
Mitochondrial Targeting of Metformin Enhances Its Activity against Pancreatic Cancer.
Topics: Animals; Antimetabolites, Antineoplastic; Apoptosis; Cell Line, Tumor; Cell Proliferation; Disease M | 2016 |
Desmoplasia suppression by metformin-mediated AMPK activation inhibits pancreatic cancer progression.
Topics: AMP-Activated Protein Kinases; Animals; Antimetabolites, Antineoplastic; Antineoplastic Combined Che | 2017 |
Krüpple-like factor 10 regulates radio-sensitivity of pancreatic cancer via UV radiation resistance-associated gene.
Topics: AMP-Activated Protein Kinases; Animals; Apoptosis; Autophagy; Cell Line, Tumor; DNA Repair; Early Gr | 2017 |
No association between metformin use and survival in patients with pancreatic cancer: An observational cohort study.
Topics: Aged; Aged, 80 and over; Diabetes Mellitus, Type 2; Female; Humans; Hypoglycemic Agents; Male; Metfo | 2017 |
Metformin induces apoptosis of pancreatic cancer cells.
Topics: Adenocarcinoma; Apoptosis; Caspase 8; Caspase 9; Cell Cycle; Cell Line, Tumor; Cell Proliferation; C | 2008 |
Metformin induces apoptosis of pancreatic cancer cells.
Topics: Adenocarcinoma; Apoptosis; Caspase 8; Caspase 9; Cell Cycle; Cell Line, Tumor; Cell Proliferation; C | 2008 |
Metformin induces apoptosis of pancreatic cancer cells.
Topics: Adenocarcinoma; Apoptosis; Caspase 8; Caspase 9; Cell Cycle; Cell Line, Tumor; Cell Proliferation; C | 2008 |
Metformin induces apoptosis of pancreatic cancer cells.
Topics: Adenocarcinoma; Apoptosis; Caspase 8; Caspase 9; Cell Cycle; Cell Line, Tumor; Cell Proliferation; C | 2008 |
Antidiabetic therapies affect risk of pancreatic cancer.
Topics: Adenocarcinoma; Age Distribution; Aged; Cancer Care Facilities; Case-Control Studies; Causality; Com | 2009 |
Metformin disrupts crosstalk between G protein-coupled receptor and insulin receptor signaling systems and inhibits pancreatic cancer growth.
Topics: Animals; Calcium; Carcinoma, Pancreatic Ductal; Cell Proliferation; DNA Replication; Down-Regulation | 2009 |
Crosstalk between insulin/insulin-like growth factor-1 receptors and G protein-coupled receptor signaling systems: a novel target for the antidiabetic drug metformin in pancreatic cancer.
Topics: Animals; Clinical Trials as Topic; Diabetes Mellitus, Type 2; Humans; Hypoglycemic Agents; Mechanist | 2010 |
The impact of type 2 diabetes and antidiabetic drugs on cancer cell growth.
Topics: Apoptosis; Cell Line, Tumor; Cell Proliferation; Deoxycytidine; Diabetes Mellitus, Type 2; Drug Resi | 2011 |
New strategies in pancreatic cancer: emerging epidemiologic and therapeutic concepts.
Topics: Animals; Diabetes Mellitus, Type 2; Disease Models, Animal; Female; Genetic Predisposition to Diseas | 2010 |
Type 2 diabetes increases and metformin reduces total, colorectal, liver and pancreatic cancer incidences in Taiwanese: a representative population prospective cohort study of 800,000 individuals.
Topics: Adult; Aged; Colorectal Neoplasms; Diabetes Mellitus, Type 2; Female; Humans; Hypoglycemic Agents; I | 2011 |
Metformin inhibits cell proliferation, migration and invasion by attenuating CSC function mediated by deregulating miRNAs in pancreatic cancer cells.
Topics: Animals; Antimetabolites, Antineoplastic; Biomarkers, Tumor; Blotting, Western; Cell Line, Tumor; Ce | 2012 |
Diabetes and pancreatic cancer.
Topics: Adipokines; Diabetes Mellitus, Type 2; Early Detection of Cancer; Humans; Hypoglycemic Agents; Insul | 2012 |
A humanized anti-IGF-1R monoclonal antibody (R1507) and/or metformin enhance gemcitabine-induced apoptosis in pancreatic cancer cells.
Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Prot | 2012 |
Metformin alters the expression profiles of microRNAs in human pancreatic cancer cells.
Topics: Animals; Cell Line, Tumor; Female; Gene Expression Regulation, Neoplastic; Humans; Metformin; Mice; | 2012 |
Use of antidiabetic agents and the risk of pancreatic cancer: a case-control analysis.
Topics: Adult; Aged; Aged, 80 and over; Case-Control Studies; Diabetes Mellitus; Female; Humans; Hypoglycemi | 2012 |
Metformin and cancer stem cells: old drug, new targets.
Topics: Animals; Cell Movement; Cell Proliferation; Female; Humans; Hypoglycemic Agents; Metformin; MicroRNA | 2012 |
Metformin and pancreatic cancer: a clue requiring investigation.
Topics: Antineoplastic Agents; Diabetes Complications; Diabetes Mellitus; Humans; Hypoglycemic Agents; Metfo | 2012 |
Metformin use is associated with better survival of diabetic patients with pancreatic cancer.
Topics: Adult; Aged; Aged, 80 and over; Diabetes Complications; Diabetes Mellitus; Female; Humans; Hypoglyce | 2012 |
Illuminating the diabetes-cancer link.
Topics: Animals; Antineoplastic Agents; Apoptosis; Blood Glucose; Breast Neoplasms; Clinical Trials as Topic | 2012 |
Metformin inhibition of mTORC1 activation, DNA synthesis and proliferation in pancreatic cancer cells: dependence on glucose concentration and role of AMPK.
Topics: AMP-Activated Protein Kinases; Antineoplastic Agents; Cell Line, Tumor; Cell Proliferation; DNA Repl | 2013 |
Prevention of pancreatic cancer induction in hamsters by metformin.
Topics: Adenocarcinoma; Animals; Cell Division; Cricetinae; Dietary Fats; DNA; Female; Glucose; Hypoglycemic | 2001 |